e424b2
Filed
Pursuant to Rule 424(b)(2)
Registration Statement
No. 333-159102
CALCULATION
OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
|
|
|
Title of Each Class of Securities
|
|
|
Amount to be
|
|
|
Maximum Offering
|
|
|
Maximum Aggregate
|
|
|
Amount of
|
to be Registered
|
|
|
Registered
|
|
|
Price Per Security
|
|
|
Offering Price
|
|
|
Registration Fee(1)
|
3.25% Notes due November 12, 2020
|
|
|
$700,000,000
|
|
|
99.949%
|
|
|
$699,643,000
|
|
|
$49,885
|
5.00% Notes due November 12, 2040
|
|
|
$300,000,000
|
|
|
99.599%
|
|
|
$298,797,000
|
|
|
$21,305
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Calculated in accordance with Rule 457(r) under the
Securities Act of 1933, as amended. The total registration fee
due for this offering is $71,190.
|
Prospectus
Supplement to Prospectus dated May 8, 2009.
Becton, Dickinson and
Company
$700,000,000 3.25% Notes
due November 12, 2020
$300,000,000 5.00% Notes due November 12,
2040
We are offering $700,000,000 aggregate principal amount of
3.25% Notes due 2020 (the 2020 notes) and
$300,000,000 aggregate principal amount of 5.00% Notes due
2040 (the 2040 notes and, together with the 2020
notes, the notes). Interest on the notes will be
payable in cash semiannually in arrears on May 12 and
November 12 of each year, beginning May 12, 2011. The
notes will be our senior unsecured obligations and will rank
equally with all of our other senior unsecured indebtedness. We
may redeem the notes, in whole at any time or from time to time
in part, at the redemption prices described in this prospectus
supplement.
The notes will not be listed on any securities exchange.
Investing in the notes involves risks that are described
in the Risk Factors section of this prospectus
supplement beginning on
page S-2.
Neither the Securities and Exchange Commission nor any other
regulatory body has approved or disapproved of these securities
or passed upon the adequacy or accuracy of this prospectus
supplement or the related prospectus. Any representation to the
contrary is a criminal offense.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020 Notes
|
|
2040 Notes
|
|
|
Per Note
|
|
Total
|
|
Per Note
|
|
Total
|
|
Public offering price
|
|
|
99.949
|
%
|
|
$
|
699,643,000
|
|
|
|
99.599
|
%
|
|
$
|
298,797,000
|
|
Underwriting discount
|
|
|
0.650
|
%
|
|
$
|
4,550,000
|
|
|
|
0.875
|
%
|
|
$
|
2,625,000
|
|
Proceeds, before expenses, to Becton, Dickinson
|
|
|
99.299
|
%
|
|
$
|
695,093,000
|
|
|
|
98.724
|
%
|
|
$
|
296,172,000
|
|
The public offering price set forth above does not include
accrued interest, if any. Interest on the notes will accrue from
November 12, 2010 and must be paid by the purchasers if the
notes are delivered after November 12, 2010.
The underwriters expect to deliver the notes to purchasers in
book-entry form only through the facilities of The Depository
Trust Company, against payment on or about
November 12, 2010.
Joint
Book-Running Managers
|
|
|
Goldman, Sachs &
Co.
|
|
Morgan Stanley
|
|
|
|
(2020 Notes)
|
|
(2040 Notes)
|
J.P. Morgan
|
|
Citi
|
Co-Managers
Mitsubishi UFJ Securities
|
|
|
|
BofA
Merrill Lynch |
BBVA
Securities |
BNP
PARIBAS |
Mizuho
Securities USA Inc. |
|
|
|
Banca
IMI |
Standard
Chartered Bank |
Wells
Fargo
Securities |
|
|
BNY
Mellon Capital Markets, LLC |
Credit
Agricole CIB |
Prospectus Supplement dated November 8, 2010.
TABLE OF
CONTENTS
Prospectus
Supplement
|
|
|
|
|
|
|
Page
|
|
|
|
|
S-ii
|
|
|
|
|
S-ii
|
|
|
|
|
S-ii
|
|
|
|
|
S-1
|
|
|
|
|
S-2
|
|
|
|
|
S-2
|
|
|
|
|
S-2
|
|
|
|
|
S-3
|
|
|
|
|
S-4
|
|
|
|
|
S-7
|
|
|
|
|
S-9
|
|
|
|
|
S-12
|
|
|
|
|
|
|
Prospectus
|
|
|
|
|
|
|
|
2
|
|
|
|
|
4
|
|
|
|
|
4
|
|
|
|
|
6
|
|
|
|
|
6
|
|
|
|
|
7
|
|
|
|
|
7
|
|
|
|
|
9
|
|
|
|
|
16
|
|
|
|
|
17
|
|
|
|
|
17
|
|
|
|
|
17
|
|
|
|
|
19
|
|
|
|
|
20
|
|
|
|
|
20
|
|
No dealer, salesperson or other person is authorized to give any
information or to represent anything not contained in this
prospectus. You must not rely on any unauthorized information or
representations. This prospectus is an offer to sell only the
notes offered hereby, but only under circumstances and in
jurisdictions where it is lawful to do so. The information
contained in this prospectus is current only as of its date.
S-i
ABOUT
THIS PROSPECTUS SUPPLEMENT
As used in this prospectus supplement, unless otherwise
specified or unless the context indicates otherwise, the terms
the Company, Becton, Dickinson,
BD, we, us, and
our refer to Becton, Dickinson and Company and its
consolidated subsidiaries. This document is in two parts. The
first part is this prospectus supplement which contains specific
information about the terms of this offering. This prospectus
supplement also adds and updates information contained in the
accompanying prospectus. The second part, the accompanying
prospectus, provides more general information about us and
securities we may offer from time to time, some of which may not
apply to this offering of securities. If there is any
inconsistency between the information in this prospectus
supplement and the accompanying prospectus, you should rely on
the information in this prospectus supplement.
WHERE YOU
CAN FIND MORE INFORMATION
We file annual, quarterly and current reports, proxy statements
and other information with the Securities and Exchange
Commission (the SEC). You may read and copy any
document that we file at the Public Reference Room of the SEC at
100 F Street, Room 1580, N.E.,
Washington, D.C. 20549. You may obtain information on the
operation of the Public Reference Room by calling the SEC at
1-800-SEC-0330.
In addition, the SEC maintains an Internet site at
http://www.sec.gov,
from which interested persons can electronically access our SEC
filings, including the registration statement and the exhibits
and schedules thereto.
The SEC allows us to incorporate by reference the
information we file with them, which means that we can disclose
important information to you by referring you to those
documents. The information incorporated by reference is an
important part of this prospectus supplement and the
accompanying prospectus, and information that we file later with
the SEC will automatically update and supersede this
information. We incorporate by reference the documents listed
below and any future filings we make with the SEC under
Sections 13(a), 13(c), 14 or 15(d) of the Securities
Exchange Act of 1934, as amended (the Exchange Act)
(other than, in each case, documents or information deemed to
have been furnished and not filed in accordance with SEC rules),
on or after the date of this prospectus until the termination of
the offering under this prospectus:
(a) Annual report on
Form 10-K
for the year ended September 30, 2009 (including the
portions of our Proxy Statement on Schedule 14A for our
2010 annual meeting of stockholders filed with the SEC on
December 23, 2009 that are incorporated by reference
therein);
(b) Quarterly reports on
Form 10-Q
for the quarters ended December 31, 2009, March 31,
2010 and June 30, 2010; and
(c) Current reports on
Form 8-K
filed with the SEC on November 4, 2009 (with respect to
Item 8.01), July 26, 2010, July 30, 2010 and
October 6, 2010.
You may request a copy of these filings at no cost, by writing
or telephoning the Office of Secretary, Becton, Dickinson and
Company, 1 Becton Drive, Franklin Lakes, New Jersey
07417-1880,
telephone (201) 847 6800.
FORWARD-LOOKING
STATEMENTS
This prospectus supplement, the accompanying prospectus and the
documents incorporated by reference therein contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words such as
plan, expect, believe,
intend, will, anticipate,
estimate and other words of similar meaning in
conjunction with, among other things, discussions of future
operations and financial performance, as well as our strategy
for growth, product development, regulatory approvals, market
position and expenditures. All statements which address
operating performance or events or developments that we expect
or anticipate will occur in the future including
statements relating to volume growth, sales and earnings per
share growth, cash flows or uses and statements expressing views
about future operating results are forward-looking
statements within the meaning of the Securities Act of 1933, as
amended (the Act).
S-ii
Forward-looking statements are based on current expectations of
future events. The forward-looking statements are and will be
based on managements then-current views and assumptions
regarding future events and operating performance, and speak
only as of their dates. Investors should realize that if
underlying assumptions prove inaccurate or unknown risks or
uncertainties materialize, actual results could vary materially
from our expectations and projections. Investors are therefore
cautioned not to place undue reliance on any forward-looking
statements. Furthermore, we undertake no obligation to update or
revise any forward-looking statements whether as a result of new
information, future events and developments or otherwise.
The following are some important factors that could cause our
actual results to differ from our expectations in any
forward-looking statements:
|
|
|
|
|
The current conditions in the global economy and financial
markets, and the potential adverse effect on liquidity and
access to capital resources for BD
and/or its
customers and suppliers, the cost of operating our business, the
demand for our products and services (particularly in countries
where governments are the primary payers of healthcare expenses
and research), or our ability to produce our products, including
the impact on developing countries. Also, the increase in
sovereign debt during the financial crisis as a result of
governmental intervention in the world economy poses additional
risks to the global financial system and economic recovery.
|
|
|
|
The consequences of the recently-enacted healthcare reform in
the United States, which could result in reduced demand for our
products, increased pricing pressures or otherwise adversely
affect BDs business.
|
|
|
|
Changes in domestic and foreign healthcare industry practices
that result in a reduction in procedures using our products or
increased pricing pressures, including the continued
consolidation among healthcare providers and trends toward
managed care and healthcare cost containment.
|
|
|
|
Regional, national and foreign economic factors, including
inflation, deflation, and fluctuations in interest rates and, in
particular, foreign currency exchange rates, and the potential
effect on our revenues, expenses, margins and credit ratings.
|
|
|
|
New or changing laws and regulations affecting our domestic and
foreign operations, or changes in enforcement practices,
including laws relating to trade, monetary and fiscal policies,
taxation (including tax reforms that could adversely impact
multinational corporations), sales practices, price controls,
licensing and regulatory requirements for new products and
products in the postmarketing phase. In particular, the
U.S. and other countries may impose new requirements
regarding registration, labeling or prohibited materials that
may require us to re-register products already on the market or
otherwise impact our ability to market our products.
Environmental laws, particularly with respect to the emission of
greenhouse gases, are also becoming more stringent throughout
the world, which may increase our costs of operations or
necessitate changes in our manufacturing plants or processes or
those of our suppliers, or result in liability to BD.
|
|
|
|
Product efficacy or safety concerns regarding our products
resulting in product recalls, regulatory action on the part of
the U.S. Food and Drug Administration (FDA) or foreign
counterparts), declining sales and product liability claims,
particularly in light of the current regulatory environment,
including increased enforcement activity by the FDA.
|
|
|
|
Competitive factors that could adversely affect our operations,
including, new product introductions (for example, new forms of
drug delivery) by our current or future competitors, increased
pricing pressure due to the impact of low cost manufacturers as
certain competitors have established manufacturing sites or have
contracted with suppliers in low-cost manufacturing locations as
a means to lower their costs, patents attained by competitors,
particularly as patents on our products expire, and new entrants
into our markets.
|
|
|
|
The effects of natural disasters, including pandemic diseases,
earthquakes, fire, wind or other destructive events, or the
effects of climate change, on our ability to manufacture our
products, (particularly where production of a product line is
concentrated in one or more plants,) or our ability to source
materials or components from suppliers that are needed for such
manufacturing.
|
|
|
|
Fluctuations in the cost and availability of oil-based resins
and other raw materials, as well as certain
sub-assemblies
and finished goods, the ability to maintain favorable supplier
arrangements and relationships
|
S-iii
|
|
|
|
|
(particularly with respect to sole-source suppliers) and the
potential adverse effects of any disruption in the availability
of such items.
|
|
|
|
|
|
Difficulties inherent in product development, including the
potential inability to successfully continue technological
innovation, complete clinical trials, obtain regulatory
approvals in the United States and abroad, obtain coverage and
adequate reimbursement for new products, or gain and maintain
market approval of products, as well as the possibility of
infringement claims by competitors with respect to patents or
other intellectual property rights, all of which can preclude or
delay commercialization of a product.
|
|
|
|
Fluctuations in the demand for products we sell to
pharmaceutical companies that are used to manufacture, or are
sold with, the products of such companies, as a result of
funding constraints, consolidation or otherwise.
|
|
|
|
Fluctuations in U.S. and international governmental funding
and policies for life sciences research.
|
|
|
|
Our ability to achieve our projected level or mix of product
sales. Our earnings forecasts are generated based on projected
volumes and sales of many product types, some of which are more
profitable than others.
|
|
|
|
Our ability to implement our ongoing upgrade of our enterprise
resource planning system, as any delays or deficiencies in the
design and implementation of our upgrade could adversely affect
our business.
|
|
|
|
Pending and potential future litigation or other proceedings
adverse to BD, including antitrust claims, product liability
claims, patent infringement claims, and the availability or
collectibility of insurance relating to any such claims.
|
|
|
|
The effect of adverse media exposure or other publicity
regarding BDs business or operations, including the effect
on BDs reputation or demand for its products.
|
|
|
|
The effects, if any, of governmental and media activities
regarding the business practices of group purchasing
organizations, which negotiate product prices on behalf of their
member hospitals with BD and other suppliers.
|
|
|
|
The effect of market fluctuations on the value of assets in
BDs pension plans and to actuarial interest rate and asset
return assumptions, which could require BD to make additional
contributions to the plans or increase our pension plan expense.
|
|
|
|
Political conditions in international markets, including civil
unrest, terrorist activity, governmental changes, restrictions
on the ability to transfer capital across borders and
expropriation of assets by a government.
|
|
|
|
Our ability to penetrate developing and emerging markets, which
also depends on economic and political conditions, and how well
we are able to acquire or form strategic business alliances with
local companies and make necessary infrastructure enhancements
to production facilities, distribution networks, sales equipment
and technology.
|
|
|
|
The effects, if any, of future healthcare reform in the
countries in which we do business, including changes in
government pricing and reimbursement policies or other cost
containment reforms.
|
|
|
|
The impact of business combinations, including any volatility in
earnings relating to acquired in-process research and
development assets, and our ability to successfully integrate
any business we may acquire.
|
|
|
|
Our ability to obtain the anticipated benefits of restructuring
programs, if any, that we may undertake.
|
|
|
|
Issuance of new or revised accounting standards by the Financial
Accounting Standards Board or the Securities and Exchange
Commission.
|
The foregoing list sets forth many, but not all, of the factors
that could impact our ability to achieve results described in
any forward-looking statements. Investors should understand that
it is not possible to predict or identify all such factors and
should not consider this list to be a complete statement of all
potential risks and uncertainties.
S-iv
RECENT
DEVELOPMENTS
Fourth Quarter and Full Year Results. On
November 3, 2010, we announced our results of operations
for our fourth quarter and year ended September 30, 2010.
For the quarter, we reported:
|
|
|
|
|
earnings per diluted share from continuing operations of $1.24,
compared with $1.20 for the fourth quarter of fiscal year 2009,
representing a 3.3% increase;
|
|
|
|
total revenues of $1.873 billion, representing a 1.0%
increase compared with the fourth quarter of fiscal year 2009;
|
|
|
|
revenues of $959 million in the BD Medical segment,
representing a 0.3% decrease compared with the fourth quarter of
fiscal year 2009;
|
|
|
|
revenues of $591 million in the BD Diagnostics segment,
representing a 2.0% increase compared with the fourth quarter of
fiscal year 2009;
|
|
|
|
revenues of $323 million in the BD Biosciences segment,
representing a 3.5% increase compared with the fourth quarter of
fiscal year 2009;
|
|
|
|
revenues in the U.S. of $832 million, representing a
1.4% increase compared with the fourth quarter of fiscal year
2009; and
|
|
|
|
revenues outside of the U.S. of $1.041 billion,
representing a 0.8% increase compared with the fourth quarter of
fiscal year 2009.
|
For the year, we reported:
|
|
|
|
|
earnings per diluted share from continuing operations of $4.90,
compared with $4.73 for the prior fiscal year, representing a
3.6% increase;
|
|
|
|
total revenues of $7.372 billion, representing a 5.5%
increase compared with the prior fiscal year;
|
|
|
|
revenues increased 6.7% in the BD Medical segment compared with
the prior fiscal year;
|
|
|
|
revenues increased 4.2% in the BD Diagnostics segment compared
with the prior fiscal year;
|
|
|
|
revenues increased 4.4% in the BD Biosciences segment compared
with the prior fiscal year;
|
|
|
|
revenues in the U.S. of $3.287 billion, representing a
5.0% increase compared with the prior fiscal year; and
|
|
|
|
revenues outside of the U.S. of $4.086 billion,
representing a 5.9% increase compared with the prior fiscal year.
|
Potential Planned Stock Repurchases. On
November 3, 2010, we also announced that subject to market
conditions we plan to repurchase up to $1.5 billion of our
common stock in 2011 and up to an additional $600 million
in 2012. We plan to fund the repurchases through ongoing cash
flow and the issuance of debt, including the notes offered
hereby.
S-1
USE OF
PROCEEDS
We estimate that the net proceeds to us from this offering will
be approximately $990,600,000, after deducting underwriting
discounts and commissions and estimated net offering expenses
payable by us. We intend to use the net proceeds from this
offering for general corporate purposes, which may include
funding for working capital, capital expenditures, repurchases
of our capital stock and acquisitions. Prior to their
application, the net proceeds may be invested in short-term
investments.
RISK
FACTORS
You should carefully consider all the information set forth in
this prospectus supplement and the accompanying prospectus and
incorporated by reference herein before deciding to invest in
the notes. In particular, we urge you to consider carefully the
factors set forth under Risk Factors in our Annual
Report on
Form 10-K
for the fiscal year ended September 30, 2009 and our
Quarterly Report on
Form 10-Q
for the quarterly period ended March 31, 2010, both of
which are incorporated by reference herein.
RATIO OF
EARNINGS TO FIXED CHARGES
The following table sets forth our historical ratio of earnings
to fixed charges for the periods indicated. This information
should be read in conjunction with the consolidated financial
statements and the accompanying notes incorporated by reference
in this prospectus supplement.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months
|
|
|
|
|
|
|
Ended
|
|
|
|
|
|
|
June 30,
|
|
|
Year Ended September 30,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
|
(In millions, except for the Ratio of Earnings to Fixed
Charges)
|
|
|
Earnings:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income From Continuing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operations Before Income Taxes
|
|
$
|
1,297.3
|
|
|
$
|
1,639.3
|
|
|
$
|
1,538.4
|
|
|
$
|
1,185.4
|
|
|
$
|
1,107.5
|
|
|
$
|
1,018.5
|
|
Interest Capitalized, Net(1)
|
|
|
(12.7
|
)
|
|
|
(9.8
|
)
|
|
|
(9.9
|
)
|
|
|
(8.2
|
)
|
|
|
(1.5
|
)
|
|
|
2.7
|
|
Fixed Charges
|
|
|
82.6
|
|
|
|
92.0
|
|
|
|
89.7
|
|
|
|
96.7
|
|
|
|
107.3
|
|
|
|
92.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings as Adjusted
|
|
$
|
1,367.2
|
|
|
$
|
1,721.5
|
|
|
$
|
1,618.2
|
|
|
$
|
1,273.9
|
|
|
$
|
1,213.3
|
|
|
$
|
1,113.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fixed Charges:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest Cost
|
|
$
|
65.8
|
|
|
$
|
69.7
|
|
|
$
|
66.2
|
|
|
$
|
73.9
|
|
|
$
|
86.0
|
|
|
$
|
70.4
|
|
Interest Allocable to Rental Expenses(2)
|
|
|
16.7
|
|
|
|
22.2
|
|
|
|
23.4
|
|
|
|
22.7
|
|
|
|
21.1
|
|
|
|
19.7
|
|
Amortization of Debt Expense
|
|
|
0.1
|
|
|
|
0.1
|
|
|
|
0.1
|
|
|
|
0.1
|
|
|
|
0.2
|
|
|
|
2.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fixed Charges
|
|
$
|
82.6
|
|
|
$
|
92.0
|
|
|
$
|
89.7
|
|
|
$
|
96.7
|
|
|
$
|
107.3
|
|
|
$
|
92.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ratio of Earnings to Fixed Charges
|
|
|
16.6
|
|
|
|
18.7
|
|
|
|
18.0
|
|
|
|
13.2
|
|
|
|
11.3
|
|
|
|
12.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Includes amortization of capitalized interest less interest
capitalized for the period. |
|
(2) |
|
Portion of rent expense representing interest. |
S-2
CAPITALIZATION
The following table sets forth our cash, short-term debt and
capitalization as of June 30, 2010, on:
|
|
|
|
|
an actual basis; and
|
|
|
|
an as adjusted basis to give effect to (i) the issuance and
sale of $700,000,000 aggregate principal amount of notes due
2020 in this offering and (ii) the issuance and sale of
$300,000,000 aggregate principal amount of notes due 2040 in
this offering.
|
You should read this table in conjunction with our consolidated
financial statements and related notes, incorporated by
reference in this prospectus supplement and the accompanying
prospectus.
|
|
|
|
|
|
|
|
|
|
|
As of June 30, 2010
|
|
|
|
Actual
|
|
|
As Adjusted
|
|
|
|
(In thousands, except par value)
|
|
|
Cash and cash equivalents
|
|
$
|
750,106
|
|
|
$
|
1,741,371
|
|
|
|
|
|
|
|
|
|
|
Short-term debt
|
|
$
|
202,221
|
|
|
$
|
202,221
|
|
|
|
|
|
|
|
|
|
|
Long-term debt:
|
|
|
|
|
|
|
|
|
3.25% Notes due 2020 offered hereby
|
|
$
|
|
|
|
$
|
700,000
|
|
5.00% Notes due 2040 offered hereby
|
|
|
|
|
|
|
300,000
|
|
Other long-term debt
|
|
$
|
1,493,400
|
|
|
$
|
1,493,400
|
|
|
|
|
|
|
|
|
|
|
Total long-term debt
|
|
$
|
1,493,400
|
|
|
$
|
2,493,400
|
|
|
|
|
|
|
|
|
|
|
Shareholders equity:
|
|
|
|
|
|
|
|
|
Common stock, $1 par value; 640,000,000 authorized shares;
232,145,867 shares issued and outstanding
|
|
|
332,662
|
|
|
|
332,662
|
|
Capital in excess of par value
|
|
|
1,600,956
|
|
|
|
1,600,956
|
|
Retained earnings
|
|
|
8,412,924
|
|
|
|
8,412,924
|
|
Deferred compensation
|
|
|
14,058
|
|
|
|
14,058
|
|
Common shares in treasury, at cost (100,516,293)
|
|
|
(4,608,348
|
)
|
|
|
(4,608,348
|
)
|
Accumulated other comprehensive loss
|
|
|
(598,375
|
)
|
|
|
(598,375
|
)
|
|
|
|
|
|
|
|
|
|
Total shareholders equity
|
|
|
5,153,877
|
|
|
|
5,153,877
|
|
|
|
|
|
|
|
|
|
|
Total capitalization
|
|
$
|
6,647,277
|
|
|
$
|
7,647,277
|
|
|
|
|
|
|
|
|
|
|
S-3
DESCRIPTION
OF NOTES
The following description of the particular terms of the notes
offered in this prospectus supplement supplements the
description of the general terms and provisions of the debt
securities in the accompanying prospectus. In this section
entitled Description of Notes, references to
Becton, Dickinson, BD, we,
us and our refer to Becton, Dickinson
and Company, as issuer of the notes and not to any of the
subsidiaries of Becton, Dickinson and Company.
The notes will be issued by Becton, Dickinson under the
indenture, dated as of March 1, 1997, between us and The
Bank of New York Mellon Trust Company, N.A., as successor
to JPMorgan Chase Bank (formerly known as The Chase Manhattan
Bank) (the Trustee). The notes are unsecured and
will rank equally with all our other unsecured and
unsubordinated indebtedness.
Terms of
the Notes
The specific terms of the 2020 notes will be as follows:
|
|
|
|
|
Title of the
notes: 3.25% Notes due
November 12, 2020
|
|
|
|
Issuer of the notes: Becton, Dickinson and
Company
|
|
|
|
Total principal amount being
issued: $700,000,000
|
|
|
|
Maturity date: November 12, 2020
|
|
|
|
Interest rate: 3.25%
|
|
|
|
Denomination: $2,000 and integral multiples of
$1,000 thereof
|
|
|
|
Date interest starts
accruing: November 12, 2010
|
|
|
|
Interest payment dates: May 12 and
November 12
|
|
|
|
First interest payment date: May 12, 2011
|
|
|
|
Regular record dates for interest: May 1 and
November 1
|
|
|
|
Redemption: See
Optional Redemption
|
|
|
|
Listing: The 2020 notes will not be listed on
any securities exchange or included in any automated quotation
system.
|
The specific terms of the 2040 notes will be as follows:
|
|
|
|
|
Title of the notes: 5.00% Notes due
November 12, 2040
|
|
|
|
Issuer of the notes: Becton, Dickinson and
Company
|
|
|
|
Total principal amount being
issued: $300,000,000
|
|
|
|
Maturity date: November 12, 2040
|
|
|
|
Interest rate: 5.00%
|
|
|
|
Denomination: $2,000 and integral multiples of
$1,000 thereof
|
|
|
|
Date interest starts
accruing: November 12, 2010
|
|
|
|
Interest payment dates: May 12 and
November 12
|
|
|
|
First interest payment date: May 12, 2011
|
|
|
|
Regular record dates for interest: May 1 and
November 1
|
|
|
|
Redemption: See Optional
Redemption
|
|
|
|
Listing: The 2040 notes will not be listed on
any securities exchange or included in any automated quotation
system.
|
S-4
We may, without notice to or consent of the holders or
beneficial owners of the notes of any series, issue additional
notes having the same ranking, interest rate, maturity
and/or other
terms as the notes of any other series. Any such additional
notes issued could be considered part of the same series of
notes under the indenture as the notes of any series offered
hereby.
An event of default for a particular series of notes under the
indenture will not necessarily constitute an event of default
for other series of notes or for any other series of debt
securities under the indenture.
Optional
Redemption
We may, at our option, redeem all or any part of the notes of
any series. If we choose to do so, we will mail a notice of
redemption to you not less than 30 days and not more than
60 days before this redemption occurs. The redemption price
will be equal to the greater of:
|
|
|
|
|
100% of the principal amount of the notes to be
redeemed; and
|
|
|
|
the sum of the present values of the Remaining Scheduled
Payments on the notes, discounted to the redemption date on a
semiannual basis, assuming a
360-day year
consisting of twelve
30-day
months, at the Treasury Rate plus 15 basis points in the case of
the 2020 notes and 15 basis points in the case of the 2040 notes.
|
The redemption price will also include interest accrued to the
date of redemption on the principal balance of the notes being
redeemed.
Treasury Rate means, for any redemption date,
the annual rate equal to the semiannual equivalent yield to
maturity of the Comparable Treasury Issue, assuming a price for
the Comparable Treasury Issue equal to the Comparable Treasury
Price, expressed as a percentage of its principal amount, for
that redemption date. The yield of the Comparable Treasury Issue
will be computed as of the second business day immediately
preceding the redemption date.
Comparable Treasury Issue means the United
States Treasury security selected by one of the investment
banking firms named below that would be used, at the time of
selection and in accordance with customary financial practice,
in pricing new issues of corporate debt securities of comparable
maturity to the applicable remaining term of the notes being
redeemed.
The investment banks we may use to select a Comparable Treasury
Issue for this purpose are Goldman, Sachs & Co.,
Morgan Stanley & Co. Incorporated, their successors
and any two other nationally recognized investment banking firms
that we will appoint from time to time that are primary dealers
of U.S. government securities in New York City, each of
whom we call a Reference Treasury Dealer. If any of
the firms named in the preceding sentence ceases to be a primary
dealer of U.S. government securities in New York City, we
will appoint another nationally recognized investment banking
firm as a substitute.
Comparable Treasury Price means, for any
redemption date:
|
|
|
|
|
the average of the Reference Treasury Dealer Quotations obtained
by the Trustee for that redemption date after excluding the
highest and lowest of those Reference Treasury Dealer
Quotations; or
|
|
|
|
if the Trustee obtains fewer than four Reference Treasury Dealer
Quotations, the average of all those quotations.
|
Reference Treasury Dealer Quotation means,
with respect to any redemption date, the average, as determined
by the Trustee, of the bid and asked prices for the Comparable
Treasury Issue, expressed in each case as a percentage of its
principal amount, quoted in writing to the Trustee by a
Reference Treasury Dealer as of 3:30 p.m., New York time,
on the third business day preceding that redemption date. The
Trustee shall seek Reference Treasury Dealer Quotations in
respect of any redemption date from each of the then-existing
Reference Treasury Dealers.
Remaining Scheduled Payments means, with
respect to each note being redeemed, the remaining scheduled
payments of principal and interest on that note that would be
due after the related redemption date but for the
S-5
redemption. If, however, the redemption date is not an interest
payment date with respect to that note, the amount of the next
succeeding scheduled interest payment on that note that would
have been due will be deemed reduced by the amount of interest
accrued on the note to the redemption date.
On and after the redemption date, the notes or any portion of
the notes called for redemption will stop accruing interest. On
or before any redemption date, we will deposit with the paying
agent or the Trustee money sufficient to pay the accrued
interest on the notes to be redeemed and their redemption price.
If less than all of the notes are redeemed, the Trustee will
choose the notes to be redeemed by any method that it deems fair
and appropriate.
Clearance
Systems
The notes have been accepted for clearance through the
Depositary Trust Company, Euroclear Bank SA/NV and
Clearstream Banking, société anonyme, Luxembourg
systems. The notes have the following codes:
|
|
|
|
|
2020 notes: CUSIP 075887 AW9 and ISIN US075887AW93
|
|
|
|
2040 notes: CUSIP 075887 AX7 and ISIN US075887AX76
|
S-6
CERTAIN
U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR
NON-U.S.
HOLDERS
The following is a discussion of certain U.S. federal
income tax consequences of the ownership and disposition of a
note by a beneficial owner that is a
Non-U.S. Holder.
A
Non-U.S. Holder
is a person or entity that, for U.S. federal income tax
purposes, is a nonresident alien individual, a foreign
corporation or a foreign estate or trust. A
Non-U.S. Holder
does not include a nonresident alien individual who is present
in the United States for 183 days or more in the taxable
year of disposition; a holder who owns, actually or
constructively, 10 percent or more of the total combined
voting power of all classes of our stock entitled to vote; a
holder that is a passive foreign investment company;
a holder that is a U.S. expatriate; or a holder that is a
controlled foreign corporation related, directly or
indirectly, to us through stock ownership. Such holders are
urged to consult their tax advisers with respect to the
particular tax consequences to them of owning and disposing of a
note.
If an entity that is classified as a partnership for
U.S. federal income tax purposes holds a note, the
U.S. federal income tax treatment of a partner will
generally depend on the status of the partner and the activities
of the partnership. Partnerships holding notes and partners in
such partnerships are urged to consult their tax advisers as to
the particular U.S. federal income tax consequences of
holding and disposing of a note.
Payments of interest on a note to any
Non-U.S. Holder
will be exempt from U.S. federal income tax (including
withholding tax) provided that interest paid on the note is not
effectively connected with the
Non-U.S. Holders
conduct of a trade or business in the United States, the
Non-U.S. Holder
does not own, actually or constructively, 10 percent or
more of the total combined voting power of all classes of our
stock entitled to vote, the
Non-U.S. Holder
is not a controlled foreign corporation related,
directly or indirectly, to us through stock ownership, the
Non-U.S. Holder
is not a bank whose receipt of interest on the note is described
in Section 881(c)(3)(A) of the Internal Revenue Code of
1986, as amended (the Code), and the
Non-U.S. Holder
certifies on Internal Revenue Service (IRS)
Form W-8BEN,
under penalties of perjury, that it is not a United States
person and provides the
Non-U.S. Holders
name and address or otherwise satisfies applicable documentation
requirements. If a
Non-U.S. Holder
cannot satisfy the above requirements, payments of interest on a
note will be subject to U.S. federal withholding tax at a
rate of 30%, unless the
Non-U.S. Holder
provides us with a properly executed IRS
Form W-8BEN
(or other applicable form) claiming an exemption from or
reduction in withholding under the benefit of an applicable
income tax treaty, or an IRS
Form W-8ECI
(or other applicable form) stating that interest paid on the
note is not subject to withholding tax because it is effectively
connected with the
Non-U.S. Holders
conduct of a trade or business in the United States.
The 30% U.S. federal withholding tax described above
generally will not apply to any payment of principal or gain
that a
Non-U.S. Holder
realizes on the sale, exchange, retirement or other disposition
of a note.
If a
Non-U.S. Holder
of a note is engaged in a trade or business in the United
States, and if interest on a note is effectively connected with
the conduct of that trade or business (and, if required by an
applicable income tax treaty, is attributable to a United States
permanent establishment), the
Non-U.S. Holder,
although exempt from the withholding tax discussed in the
preceding paragraph, will generally be subject to
U.S. federal income tax in the same manner as a United
States person, subject to an applicable income tax treaty
providing otherwise, except that the
Non-U.S. Holder
will be required to provide to us a properly executed IRS
Form W-8ECI
in order to claim an exemption from withholding tax. Interest on
a note paid to a corporate
Non-U.S. Holder
may also be subject to a branch profits tax at a rate of 30% (or
a lower rate as provided in an applicable tax treaty).
Any gain realized on the disposition of a note generally will
not be subject to U.S. federal income tax unless the gain
is effectively connected with the
Non-U.S. Holders
conduct of a trade or business in the United States (and, if
required by an applicable income tax treaty, is attributable to
a United States permanent establishment) or the
Non-U.S. Holder
is an individual who is present in the United States for
183 days or more in the taxable year of that disposition,
and certain other conditions are met.
Generally, we must report to the IRS and to
Non-U.S. Holders
the amount of interest paid to
Non-U.S. Holders
and the amount of tax, if any, withheld with respect to those
payments. Copies of the information returns reporting such
interest payments and any withholding may also be made available
to the tax authorities in the country in which the
Non-U.S. Holder
resides under the provisions of an applicable income tax treaty.
S-7
In general,
Non-U.S. Holders
will not be subject to backup withholding with respect to
payments on the note that we make provided that we do not have
actual knowledge or reason to know that such
Non-U.S. Holder
is a United States person as defined under the Code, and the
Non-U.S. Holder
certifies on IRS
Form W-8BEN,
under penalties of perjury, that it is not a United States
person and provides the
Non-U.S. Holders
name and address or otherwise satisfies applicable documentation
requirements.
Information reporting and, depending on the circumstances,
backup withholding will apply to the proceeds of a sale of notes
within the United States or conducted through certain United
States-related financial intermediaries, unless the
Non-U.S. Holder
certifies, under penalties of perjury, that it is not a United
States person (and the payor does not have actual knowledge or
reason to know that it is a United States person as defined
under the Code), or such holder otherwise establishes an
exemption.
Any amounts withheld under the backup withholding rules will be
allowed as a refund or a credit against the
Non-U.S. Holders
U.S. federal income tax liability, provided the required
information is timely furnished to the IRS.
The preceding discussion is based on the Code and administrative
pronouncements, judicial decisions and final, temporary and
proposed Treasury Regulations, changes to any of which
subsequent to the date of this prospectus supplement may affect
the tax consequences described herein. This discussion does not
address U.S. federal estate taxation, other aspects of
U.S. federal income taxation or any tax consequences
arising under the laws of any foreign jurisdiction that may be
relevant to
Non-U.S. Holders
in light of their particular circumstances.
Non-U.S. Holders
are urged to consult their tax advisers with respect to the
particular tax consequences to them of owning and disposing of a
note.
S-8
UNDERWRITING
Each of the underwriters named below has severally agreed,
subject to the terms and conditions of the Underwriting
Agreement with Becton, Dickinson dated the date hereof to
purchase the principal amount of notes set forth below opposite
its name. The underwriters are committed to purchase all of the
notes if any notes are purchased.
|
|
|
|
|
|
|
|
|
|
|
Principal
|
|
|
Principal
|
|
|
|
Amount
|
|
|
Amount
|
|
|
|
of 2020
|
|
|
of 2040
|
|
|
|
Securities to
|
|
|
Securities to
|
|
Underwriter
|
|
be Purchased
|
|
|
be Purchased
|
|
|
Goldman, Sachs & Co.
|
|
$
|
245,000,000
|
|
|
$
|
105,000,000
|
|
Morgan Stanley & Co. Incorporated
|
|
|
245,000,000
|
|
|
|
105,000,000
|
|
J.P. Morgan Securities LLC
|
|
|
44,100,000
|
|
|
|
18,900,000
|
|
Citigroup Global Markets Inc.
|
|
|
34,300,000
|
|
|
|
14,700,000
|
|
Banca IMI S.p.A.
|
|
|
9,800,000
|
|
|
|
4,200,000
|
|
BBVA Securities Inc.
|
|
|
14,700,000
|
|
|
|
6,300,000
|
|
BNP Paribas Securities Corp.
|
|
|
14,700,000
|
|
|
|
6,300,000
|
|
BNY Mellon Capital Markets, LLC
|
|
|
7,000,000
|
|
|
|
3,000,000
|
|
Credit Agricole Securities (USA) Inc.
|
|
|
7,000,000
|
|
|
|
3,000,000
|
|
Mitsubishi UFJ Securities (USA), Inc.
|
|
|
29,400,000
|
|
|
|
12,600,000
|
|
Mizuho Securities USA Inc.
|
|
|
14,700,000
|
|
|
|
6,300,000
|
|
Merrill Lynch, Pierce, Fenner & Smith Incorporated
|
|
|
14,700,000
|
|
|
|
6,300,000
|
|
Standard Chartered Bank
|
|
|
9,800,000
|
|
|
|
4,200,000
|
|
Wells Fargo Securities, LLC
|
|
|
9,800,000
|
|
|
|
4,200,000
|
|
Total
|
|
$
|
700,000,000
|
|
|
$
|
300,000,000
|
|
The notes are each new issues of securities with no established
trading market. Becton, Dickinson has been advised by the
underwriters that the underwriters intend to make a market in
the notes but are not obligated to do so and may discontinue
market making at any time without notice. No assurance can be
given as to the liquidity of the trading market for the notes.
Becton, Dickinson has agreed to indemnify the several
underwriters against certain liabilities, including liabilities
under the Securities Act of 1933, as amended.
The underwriters propose to offer the notes initially at the
respective offering prices on the cover page of this prospectus
supplement. The underwriters may sell notes to securities
dealers at a discount from the initial public offering price of
up to 0.40% of the principal amount in the case of the 2020
notes and 0.50% of the principal amount in the case of the 2040
notes. These securities dealers may resell any notes purchased
from the underwriters to other brokers or dealers at a discount
from the initial public offering price of up to 0.25% of the
principal amount in the case of the 2020 notes and 0.25% of the
principal amount in the case of the 2040 notes. If the
underwriters cannot sell all the notes at the initial offering
price, they may change the offering price and the other selling
terms.
The offering of the notes by the underwriters is subject to
receipt and acceptance and subject to the underwriters
right to reject any order in whole or in part.
Banca IMI S.p.A and Standard Chartered Bank will not effect any
offers or sales of any notes in the United States unless it is
through one or more U.S. registered broker-dealers as
permitted by the regulations of FINRA.
In order to facilitate the offering of the notes, the
underwriters may engage in transactions that stabilize, maintain
or support the price of such notes, as the case may be, for a
limited period after the issue date. Specifically, the
underwriters may over-allot in connection with the offering,
creating a short position in the notes for their own account. In
addition, to cover over-allotments or to stabilize the price of
the notes, the underwriters may bid for, and purchase, notes in
the open market. Any of these activities may stabilize or
maintain the market price of the notes
S-9
above independent market levels. The underwriters are not
required to engage in these activities, and may end any of these
activities at any time. These transactions may be effected in
the
over-the-counter
market or otherwise.
The underwriters also may impose a penalty bid. This occurs when
a particular underwriter repays to the underwriters a portion of
the underwriting discount received by it because the
representatives have repurchased notes sold by or for the
account of such underwriter in stabilizing or short covering
transactions.
The underwriters and their respective affiliates are full
service financial institutions engaged in various activities,
which may include securities trading, commercial and investment
banking, financial advisory, investment management, investment
research, principal investment, hedging, financing and brokerage
activities. Certain of the underwriters and their respective
affiliates have, from time to time, performed, and may in the
future perform, various financial advisory and investment
banking services for Becton, Dickinson, for which they received
or will receive customary fees and expenses.
In the ordinary course of their various business activities, the
underwriters and their respective affiliates may make or hold a
broad array of investments and actively trade debt and equity
securities (or related derivative securities) and financial
instruments (including bank loans) for their own account and for
the accounts of their customers, and such investment and
securities activities may involve securities
and/or
instruments of Becton, Dickinson. The underwriters and their
respective affiliates may also make investment recommendations
and/or
publish or express independent research views in respect of such
securities or instruments and may at any time hold, or recommend
to clients that they acquire, long
and/or short
positions in such securities and instruments.
Becton, Dickinson estimates that its share of the total expenses
of the offering, excluding underwriting discounts and
commissions, will be approximately $668,200.
European
Economic Area
In relation to each Member State of the European Economic Area
which has implemented the Prospectus Directive (each, a
Relevant Member State), each underwriter has
represented and agreed that with effect from and including the
date on which the Prospectus Directive is implemented in that
Relevant Member State (the Relevant Implementation
Date) it has not made and will not make an offer of notes
to the public in that Relevant Member State prior to the
publication of a prospectus in relation to the notes which has
been approved by the competent authority in that Relevant Member
State or, where appropriate, approved in another Relevant Member
State and notified to the competent authority in that Relevant
Member State, all in accordance with the Prospectus Directive,
except that it may, with effect from and including the Relevant
Implementation Date, make an offer of notes to the public in
that Relevant Member State at any time:
(a) to legal entities which are authorized or regulated to
operate in the financial markets or, if not so authorized or
regulated, whose corporate purpose is solely to invest in
securities;
(b) to any legal entity which has two or more of
(1) an average of at least 250 employees during the
last financial year; (2) a total balance sheet of more than
43,000,000 and (3) an annual net turnover of more
than 50,000,000, as shown in its last annual or
consolidated accounts;
(c) to fewer than 100 natural or legal persons (other than
qualified investors as defined in the Prospectus Directive)
subject to obtaining the prior consent of the representatives
for any such offer; or
(d) in any other circumstances which do not require the
publication by us of a prospectus pursuant to Article 3 of
the Prospectus Directive.
For the purposes of this provision, the expression an
offer of notes to the public in relation to any
notes in any Relevant Member State means the communication in
any form and by any means of sufficient information on the terms
of the offer and the notes to be offered so as to enable an
investor to decide to purchase or subscribe the notes, as the
same may be varied in that Member State by any measure
implementing the Prospectus Directive in that Member State, and
the expression Prospectus Directive means Directive
2003/71/EC and includes any relevant implementing measure in
each Relevant Member State.
S-10
Each underwriter has represented and agreed that:
(a) it has only communicated or caused to be communicated
and will only communicate or cause to be communicated an
invitation or inducement to engage in investment activity
(within the meaning of Section 21 of the Financial Services
and Markets Act 2000 (FSMA)) received by it in
connection with the issue or sale of the notes in circumstances
in which Section 21(1) of the FSMA does not apply to
us; and
(b) it has complied and will comply with all applicable
provisions of the FSMA with respect to anything done by it in
relation to the notes in, from or otherwise involving the United
Kingdom.
The notes may not be offered or sold by means of any document
other than (i) in circumstances which do not constitute an
offer to the public within the meaning of the Companies
Ordinance (Cap.32, Laws of Hong Kong), or (ii) to
professional investors within the meaning of the
Securities and Futures Ordinance (Cap.571, Laws of Hong Kong)
and any rules made thereunder, or (iii) in other
circumstances which do not result in the document being a
prospectus within the meaning of the Companies
Ordinance (Cap.32, Laws of Hong Kong), and no advertisement,
invitation or document relating to the notes may be issued or
may be in the possession of any person for the purpose of issue
(in each case whether in Hong Kong or elsewhere), which is
directed at, or the contents of which are likely to be accessed
or read by, the public in Hong Kong (except if permitted to do
so under the laws of Hong Kong) other than with respect to notes
which are or are intended to be disposed of only to persons
outside Hong Kong or only to professional investors
within the meaning of the Securities and Futures Ordinance (Cap.
571, Laws of Hong Kong) and any rules made thereunder.
The notes have not been and will not be registered under the
Financial Instruments and Exchange Law of Japan (the Financial
Instruments and Exchange Law), and each underwriter has agreed
that it will not offer or sell any notes, directly or
indirectly, in Japan or to, or for the benefit of, any resident
of Japan (which term as used herein means any person resident in
Japan, including any corporation or other entity organized under
the laws of Japan), or to others for re-offering or resale,
directly or indirectly, in Japan or to a resident of Japan,
except pursuant to an exemption from the registration
requirements of, and otherwise in compliance with, the Financial
Instruments and Exchange Law and any other applicable laws,
regulations and ministerial guidelines of Japan.
This prospectus has not been registered as a prospectus with the
Monetary Authority of Singapore. Accordingly, this prospectus
and any other document or material in connection with the offer
or sale, or invitation for subscription or purchase, of the
notes may not be circulated or distributed, nor may the notes be
offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to
persons in Singapore other than (i) to an institutional
investor under Section 274 of the Securities and Futures
Act, Chapter 289 of Singapore (the SFA),
(ii) to a relevant person, or any person pursuant to
Section 275(1A), and in accordance with the conditions,
specified in Section 275 of the SFA or (iii) otherwise
pursuant to, and in accordance with the conditions of, any other
applicable provision of the SFA. Where the notes are subscribed
or purchased under Section 275 by a relevant person which
is: (a) a corporation (which is not an accredited investor)
the sole business of which is to hold investments and the entire
share capital of which is owned by one or more individuals, each
of whom is an accredited investor; or (b) a trust (where
the trustee is not an accredited investor) whose sole purpose is
to hold investments and each beneficiary is an accredited
investor, shares, debentures and units of shares and debentures
of that corporation or the beneficiaries rights and
interest in that trust shall not be transferable for
6 months after that corporation or that trust has acquired
the notes under Section 275 except: (1) to an
institutional investor under Section 274 of the SFA or to a
relevant person, or any person pursuant to Section 275(1A),
and in accordance with the conditions, specified in
Section 275 of the SFA; (2) where no consideration is
given for the transfer; or (3) by operation of law.
S-11
VALIDITY
OF NOTES
Jeffrey S. Sherman, Senior Vice President and General Counsel of
Becton, Dickinson, will issue an opinion about certain New
Jersey law matters in connection with the offering of the notes
for Becton, Dickinson. The validity of the notes offered hereby
will be passed upon for Becton, Dickinson by Simpson
Thacher & Bartlett LLP, New York, New York, and for
the underwriters by Sullivan & Cromwell LLP, New York,
New York.
S-12
PROSPECTUS
BECTON,
DICKINSON AND COMPANY
COMMON
STOCK
PREFERRED STOCK
DEBT SECURITIES
WARRANTS
PURCHASE CONTRACTS
UNITS
We may offer from time to time common stock, preferred stock,
debt securities, warrants, purchase contracts or units that may
include any of these securities or securities of other entities.
Specific terms of these securities will be provided in
supplements to this prospectus. You should read this prospectus
and any supplement carefully before you invest.
Our common stock is listed on the New York Stock Exchange under
the trading symbol BDX.
Investing in these securities involves certain risks. See
Risk Factors beginning on page 6 of our annual
report on
Form 10-K
for the year ended September 30, 2008, which is
incorporated by reference herein.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved these
securities, or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal
offense.
The date of this prospectus is May 8, 2009
You should rely only on the information contained in or
incorporated by reference in this prospectus. We have not
authorized anyone to provide you with different information. We
are not making an offer of these securities in any state where
the offer is not permitted. You should not assume that the
information contained in or incorporated by reference in this
prospectus is accurate as of any date other than their
respective dates. The terms BD, we,
us, and our refer to Becton, Dickinson
and Company.
TABLE OF
CONTENTS
|
|
|
|
|
|
|
Page
|
|
|
|
|
2
|
|
|
|
|
4
|
|
|
|
|
4
|
|
|
|
|
6
|
|
|
|
|
6
|
|
|
|
|
7
|
|
|
|
|
7
|
|
|
|
|
9
|
|
|
|
|
16
|
|
|
|
|
17
|
|
|
|
|
17
|
|
|
|
|
17
|
|
|
|
|
19
|
|
|
|
|
20
|
|
|
|
|
20
|
|
BECTON,
DICKINSON AND COMPANY
Becton, Dickinson and Company was incorporated under the laws of
the State of New Jersey in November 1906, as successor to a New
York business started in 1897.
We are a medical technology company engaged principally in the
manufacture and sale of a broad range of medical supplies,
devices, laboratory equipment and diagnostic products used by
healthcare institutions, life science researchers, clinical
laboratories, industry and the general public. Our operations
consist of three worldwide business segments:
BD Medical,
BD Diagnostics, and
BD Biosciences.
BD Medical produces a broad array of medical devices that are
used in a wide range of healthcare settings. They include many
safety-engineered injection, infusion and surgery products. BD
Medicals principal product lines include needles, syringes
and intravenous catheters for medication delivery;
prefilled IV flush syringes; syringes and pen needles for
the self injection of insulin and other drugs used in the
treatment of diabetes; prefillable drug delivery devices
provided to pharmaceutical companies and sold to end-users as
drug/device combinations; surgical blades/scalpels and regional
anesthesia needles and trays; critical care monitoring devices;
ophthalmic surgical instruments; sharps disposal containers; and
home healthcare products. The primary markets served by
BD Medical are hospitals and clinics; physicians
office practices; consumers and retail pharmacies; public health
agencies; pharmaceutical companies; and healthcare workers.
BD Diagnostics provides products for the safe collection and
transport of diagnostic specimens and instrumentation for
analysis across a broad range of infectious disease testing,
including healthcare-associated infections (HAIs). BD
Diagnostics principal products and services include
integrated systems for specimen collection; an extensive line of
safety-engineered collection products and systems; plated media;
automated blood culturing systems; molecular testing systems for
sexually transmitted diseases and HAIs; microorganism
identification and drug susceptibility systems; liquid-based
cytology systems for cervical cancer screenings; and rapid
diagnostic assays. BD Diagnostics serves hospitals, laboratories
and clinics; reference laboratories; blood banks; healthcare
workers; patients; physicians office practices; and
industrial microbiology laboratories.
BD Biosciences produces research and clinical tools that
facilitate the study of cells, and the components of cells, to
gain a better understanding of normal and disease processes.
That information is used to aid the discovery and development of
new drugs and vaccines, and to improve the diagnosis and
management of diseases. BD Biosciences principal
product lines include fluorescence activated cell sorters and
analyzers; cell imaging systems, monoclonal antibodies and kits
for performing cell analysis; reagent systems for life sciences
research; tools to aid in drug discovery and growth of tissue
and cells; and cell culture media supplements for
biopharmaceutical manufacturing; and diagnostic assays. The
primary markets served by BD Biosciences are research and
clinical laboratories; hospitals and transplant centers; blood
banks; and biotechnology and pharmaceutical companies.
Our products are manufactured and sold worldwide. Our operations
outside the United States are conducted in Canada and in the
following geographic regions: Europe (including the Middle East
and Africa); Japan; Asia Pacific (which includes Australia and
all of Asia except Japan); and Latin America (which includes
Mexico and Brazil). The principal products sold by BD outside of
the United States include hypodermic needles and syringes,
insulin syringes and pen needles, diagnostic systems, BD
Vacutainertm
brand blood collection products, BD
Hypaktm
brand prefillable syringe systems, infusion therapy products,
flow cytometry instruments and reagents, and disposable
laboratory products. BD has manufacturing operations outside the
United States in Brazil, Canada, China, France, Germany, India,
Ireland, Japan, Mexico, Pakistan, Singapore, South Korea, Spain,
Sweden and the United Kingdom.
We market our products and services in the United States and
internationally through independent distribution channels, as
well as directly to end-users.
Our principal executive offices are located at 1 Becton Drive,
Franklin Lakes, New Jersey
07417-1880,
and our telephone number is
(201) 847-6800.
We maintain a website at www.bd.com where general information
about us is
2
available. The information on our website is not part of this
prospectus and you should rely only on the information contained
in this prospectus and the documents we incorporate by reference
herein when making a decision as to whether to invest in any of
our securities offered pursuant to this prospectus.
About
this Prospectus
This prospectus is part of a registration statement that we
filed with the Securities Exchange Commission (the
SEC) utilizing a shelf registration
process. Under this shelf process, we may sell any combination
of the securities described in this prospectus in one or more
offerings. This prospectus provides you with a general
description of the securities we may offer. Each time we sell
securities, we will provide a prospectus supplement that will
contain specific information about the terms of that offering.
The prospectus supplement may also add, update or change
information contained in this prospectus. You should read both
this prospectus and any prospectus supplement together with
additional information described under the heading Where
You Can Find More Information.
3
WHERE YOU
CAN FIND MORE INFORMATION
We file annual, quarterly and current reports, proxy statements
and other information with the SEC. You may read and copy any
document that we file at the Public Reference Room of the SEC at
100 F Street, Room 1580, N.E.,
Washington, D.C. 20549. You may obtain information on the
operation of the Public Reference Room by calling the SEC at
1-800-SEC-0330.
In addition, the SEC maintains an Internet site at
http://www.sec.gov,
from which interested persons can electronically access our SEC
filings, including the registration statement and the exhibits
and schedules thereto.
The SEC allows us to incorporate by reference the
information we file with them, which means that we can disclose
important information to you by referring you to those
documents. The information incorporated by reference is an
important part of this prospectus, and information that we file
later with the SEC will automatically update and supersede this
information. We incorporate by reference the documents listed
below and any future filings we make with the SEC under
Sections 13(a), 13(c), 14 or 15(d) of the Securities
Exchange Act of 1934, as amended (the Exchange Act)
(other than, in each case, documents or information deemed to
have been furnished and not filed in accordance with SEC rules),
on or after the date of this prospectus until the termination of
the offering under this prospectus:
(a) Quarterly reports on
Form 10-Q
for the quarters ended December 31, 2008 and March 31,
2009;
(b) Annual report on
Form 10-K
for the year ended September 30, 2008;
(c) Current reports on Form 8-K filed with the SEC on
November 5, 2008, December 9, 2008, January 7,
2009, April 28, 2009 and May 8, 2009 (except for the
information furnished pursuant to Item 2.02 of
Form 8-K and the furnished exhibits related to that
information);
(d) Definitive proxy statement on Form 14A filed with
the SEC on December 23, 2008;
(e) The description of our common stock, par value $1.00
per share contained in a registration statement under the
Exchange Act, including any amendment or report filed for the
purpose of updating such description; and
(f) The description of our preferred stock, par value $1.00
per share contained in a registration statement under the
Exchange Act, including any amendment or report filed for the
purpose of updating such description.
You may request a copy of these filings at no cost, by writing
or telephoning the office of Secretary, Becton, Dickinson and
Company, 1 Becton Drive, Franklin Lakes, New Jersey
07417-1880,
telephone
(201) 847-6800.
SPECIAL
NOTE ON FORWARD-LOOKING STATEMENTS
This prospectus includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
We may from time to time make certain forward-looking statements
in publicly released materials, both written and oral, including
statements contained in this prospectus and other filings with
the SEC. Forward-looking statements may be identified by the use
of words such as plan, expect,
believe, intend, will,
anticipate, estimate and other words of
similar meaning in conjunction with, among other things,
discussions of future operations and financial performance, as
well as our strategy for growth, product development, regulatory
approvals, market position and expenditures. All statements
which address operating performance or events or developments
that we expect or anticipate will occur in the
future including statements relating to volume
growth, sales and earnings per share growth, cash flows or uses
and statements expressing views about future operating
results are forward-looking statements within the
meaning of the Securities Act of 1933, as amended (the
Act).
Forward-looking statements are based on current expectations of
future events. The forward-looking statements are and will be
based on managements then-current views and assumptions
regarding future events and operating performance, and speak
only as of their dates. Investors should realize that if
underlying assumptions prove inaccurate or unknown risks or
uncertainties materialize, actual results could vary materially
from our expectations and projections. Investors are therefore
cautioned not to place undue reliance on any forward-looking
4
statements. Furthermore, we undertake no obligation to update or
revise any forward-looking statements whether as a result of new
information, future events and developments or otherwise.
The following are some important factors that could cause our
actual results to differ from our expectations in any
forward-looking statements:
|
|
|
|
|
The current economic crisis and instability in the global
financial markets and the potential adverse effect on liquidity
and capital resources for BD or its customers and suppliers, the
cost of operating our business, the demand for our products and
services, or the ability to produce our products, including the
impact on developing countries and their demand for our products.
|
|
|
|
Regional, national and foreign economic factors, including
inflation, deflation and fluctuations in interest rates and
foreign currency exchange rates and the potential effect of such
fluctuations on revenues, expenses and resulting margins, as
well as competition in certain markets.
|
|
|
|
Fluctuations in the cost and availability of oil-based resins
and other raw materials, as well as certain sub-assemblies and
finished goods, and the ability to maintain favorable supplier
arrangements and relationships (particularly with respect to
sole-source suppliers) and the potential adverse effects of any
disruption in the availability of such items.
|
|
|
|
We operate in a highly competitive environment. New product
introductions by our current or future competitors (for example,
new forms of drug delivery) could adversely affect our ability
to compete in the global market. Patents attained by
competitors, particularly as patents on our products expire, may
also adversely impact our competitive position. Certain
competitors have established manufacturing sites or have
contracted with suppliers in low-cost manufacturing locations as
a means to lower their costs. New entrants may also appear.
|
|
|
|
We sell certain products to pharmaceutical companies that are
used to manufacture, or are sold with, products by such
companies. As a result, fluctuations in demand for the products
of these pharmaceutical companies could adversely affect our
operating results.
|
|
|
|
Changes in domestic and foreign healthcare industry practices
and regulations resulting in increased pricing pressures,
including the continued consolidation among healthcare
providers; trends toward managed care and healthcare cost
containment; and government laws and regulations relating to
sales and promotion, reimbursement and pricing generally.
|
|
|
|
The effects, if any, of governmental and media activities
regarding the business practices of group purchasing
organizations, which negotiate product prices on behalf of their
member hospitals with BD and other suppliers.
|
|
|
|
Our ability to obtain the anticipated benefits of restructuring
programs, if any, that we may undertake.
|
|
|
|
Our ability to implement the upgrade of our enterprise resource
planning system. Any delays or deficiencies in the design and
implementation of our upgrade could adversely affect our
business.
|
|
|
|
Adoption of, or changes in, government laws and regulations
affecting domestic and foreign operations, including those
relating to trade, monetary and fiscal policies, taxation
(including tax reforms proposed by the Obama administration that
could adversely impact multinational corporations),
environmental matters, sales practices, price controls,
licensing and regulatory approval of new products, regulatory
requirements for products in the postmarketing phase, or changes
in enforcement practices with respect to any such laws and
regulations. In particular, environmental laws, particularly
with respect to the emission of greenhouse gases, are becoming
more stringent throughout the world, which may increase our
costs of operations or necessitate changes in our manufacturing
plants or processes.
|
|
|
|
Fluctuations in U.S. and international governmental funding
and policies for life sciences research.
|
|
|
|
Difficulties inherent in product development, including the
potential inability to successfully continue technological
innovation, complete clinical trials, obtain regulatory
approvals in the United States and abroad, obtain coverage and
adequate reimbursement for new products, or gain and maintain
market approval of products, as well as the possibility of
encountering infringement claims by competitors with respect to
patent or other intellectual property rights, all of which can
preclude or delay commercialization of a product.
|
5
|
|
|
|
|
Pending and potential litigation or other proceedings adverse to
BD, including antitrust claims, product liability claims, patent
infringement claims and the availability or collectibility of
insurance relating to any such claims.
|
|
|
|
The effects, if any, of adverse media exposure or other
publicity regarding BDs business or operations.
|
|
|
|
Our ability to achieve the projected level or mix of product
sales. Our earnings forecasts are generated based on such
projected volumes and sales of many product types, some of which
are more profitable than others.
|
|
|
|
The effect of market fluctuations on the value of assets in
BDs pension plans and the possibility that BD may need to
make additional contributions to the plans as a result of any
decline in the value of such assets.
|
|
|
|
Our ability to effect infrastructure enhancements and
incorporate new systems technologies into our operations.
|
|
|
|
Product efficacy or safety concerns resulting in product
recalls, regulatory action on the part of the U.S. Food and
Drug Administration (or foreign counterparts) or declining sales.
|
|
|
|
Political conditions in international markets, including civil
unrest, terrorist activity, governmental changes, restrictions
on the ability to transfer capital across borders and
expropriation of assets by a government.
|
|
|
|
The effects of natural disasters, including pandemic diseases,
earthquakes, fire, or the effects of climate change on our
ability to manufacture our products, particularly where
production of a product line is concentrated in one or more
plants, or on our ability to source components from suppliers
that are needed for such manufacturing.
|
|
|
|
Our ability to penetrate developing and emerging markets, which
also depends on economic and political conditions, and how well
we are able to acquire or form strategic business alliances with
local companies and make necessary infrastructure enhancements
to production facilities, distribution networks, sales equipment
and technology.
|
|
|
|
The impact of business combinations, including acquisitions and
divestitures, both internally on BD and externally on the
healthcare industry.
|
|
|
|
Issuance of new or revised accounting standards by the Financial
Accounting Standards Board or the SEC.
|
The foregoing list sets forth many, but not all, of the factors
that could impact our ability to achieve results described in
any forward-looking statements. Investors should understand that
it is not possible to predict or identify all such factors and
should not consider this list to be a complete statement of all
potential risks and uncertainties.
USE OF
PROCEEDS
Unless otherwise indicated in a prospectus supplement, the net
proceeds from the sale of the securities will be used for
general corporate purposes, including working capital,
acquisitions, retirement of debt and other business
opportunities.
RATIO OF
EARNINGS TO FIXED CHARGES
The following table sets forth our ratio of earnings to fixed
charges for the periods indicated.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six-Months Ended
|
|
|
|
|
|
|
March 31,
|
|
|
Year Ended September 30,
|
|
|
|
2009
|
|
|
2008
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
2004
|
|
|
Ratio of earnings to fixed charges
|
|
|
20.2
|
|
|
|
17.5
|
|
|
|
18.2
|
|
|
|
13.4
|
|
|
|
11.5
|
|
|
|
12.3
|
|
|
|
10.8
|
|
The ratios of earnings to fixed charges were calculated by
dividing earnings by fixed charges. Earnings were calculated by
adding income from continuing operations before income taxes;
net capitalized interest (amortization of capitalized interest
less interest capitalized for the period); and fixed charges.
Fixed charges were calculated by adding total interest costs;
interest allocable to rental expense; and amortization of debt
expense.
6
We have not paid a preference security dividend for any of the
periods presented.
DESCRIPTION
OF SECURITIES
This prospectus contains a summary of the securities that BD may
sell. These summaries are not meant to be a complete description
of each security. However, this prospectus and the accompanying
prospectus supplement contain the material terms of the
securities being offered.
DESCRIPTION
OF CAPITAL STOCK
General
The following description of our capital stock is based upon our
certificate of incorporation, our bylaws and applicable
provisions of law. We have summarized certain portions of our
certificate of incorporation and bylaws below. The summary is
not complete. The certificate of incorporation and bylaws are
incorporated by reference in the registration statement for
these securities that we have filed with the SEC, and have been
filed as exhibits to our quarterly report on
Form 10-Q
for the quarter ended March 31, 2009. You should read the
certificate of incorporation and bylaws for the provisions that
are important to you.
We have 640,000,000 shares of authorized common stock,
$1.00 par value per share, of which 239,533,755 shares
were outstanding as of March 31, 2009. We also have
5,000,000 shares of authorized preferred stock,
$1.00 par value per share, but none were outstanding as of
March 31, 2009.
Our bylaws deny stockholders the right to call a special meeting
of stockholders. Our bylaws also provide that only the Chairman
of the Board, the President or the board of directors may call
special meetings of the stockholders.
Common
Stock
Listing
Our outstanding shares of common stock are listed on the New
York Stock Exchange (the NYSE) under the symbol
BDX. Any additional common stock we issue also will
be listed on the NYSE.
Dividends
Holders of our common stock are entitled to receive dividends
when, as and if declared by our board of directors out of any
funds legally available for dividends. We will pay dividends on
our common stock only if we have paid or provided for dividends
on any outstanding series of preferred stock for all prior
periods. Holders of our common stock are entitled to one vote
for each share that they hold and are vested with all of the
voting power except as our board of directors has provided, or
may provide in the future with respect to any class or series of
preferred stock that the board of directors may hereafter
authorize. Shares of our common stock are not redeemable and
have no subscription, conversion or preemptive rights.
Fully
Paid
Outstanding shares of our common stock are validly issued, fully
paid and non-assessable. Any additional common stock we issue
will also be fully paid and non-assessable. Holders of our
common stock are not, and will not be, subject to any liability
as stockholders.
Other
Rights
We will notify common shareholders of any shareholders
meetings according to applicable law. If we liquidate, dissolve
or wind-up
our business, either voluntarily or not, common shareholders
will share equally in the assets remaining after we pay our
creditors and preferred shareholders. The holders of common
stock have no preemptive rights to purchase our shares of stock.
Shares of common stock are not subject to any redemption or
sinking fund provisions and are not convertible into any of our
other securities.
7
Preferred
Stock
Our board of directors may, from time to time, authorize the
issuance of one or more classes or series of preferred stock
without stockholder approval.
The following description of the terms of the preferred stock
sets forth certain general terms and provisions of our
authorized preferred stock. If we offer preferred stock, a
description will be filed with the SEC and the specific
designations and rights will be described in the prospectus
supplement, including the following terms:
|
|
|
|
|
the series, the number of shares offered and the liquidation
value of the preferred stock;
|
|
|
|
the price at which the preferred stock will be issued;
|
|
|
|
the dividend rate, the dates on which the dividends will be
payable and other terms relating to the payment of dividends on
the preferred stock;
|
|
|
|
the voting rights of the preferred stock;
|
|
|
|
whether the preferred stock is redeemable or subject to a
sinking fund, and the terms of any such redemption or sinking
fund;
|
|
|
|
whether the preferred stock is convertible or exchangeable for
any other securities, and the terms of any such
conversion; and
|
|
|
|
any additional rights, preferences, qualifications, limitations
and restrictions of the preferred stock.
|
The description of the terms of the preferred stock to be set
forth in an applicable prospectus supplement will not be
complete and will be subject to and qualified in its entirety by
reference to the certificate of amendment to our certificate of
incorporation relating to the applicable series of preferred
stock. The registration statement of which this prospectus forms
a part will include the certificate of amendment as an exhibit
or incorporate it by reference.
Undesignated preferred stock may enable our board of directors
to render more difficult or to discourage an attempt to obtain
control of us by means of a tender offer, proxy contest, merger
or otherwise, and to thereby protect the continuity of our
management. The issuance of shares of preferred stock may
adversely affect the rights of the holders of our common stock.
For example, any preferred stock issued may rank prior to our
common stock as to dividend rights, liquidation preference or
both, may have full or limited voting rights and may be
convertible into shares of common stock. As a result, the
issuance of shares of preferred stock may discourage bids for
our common stock or may otherwise adversely affect the market
price of our common stock or any existing preferred stock.
The preferred stock will, when issued, be fully paid and
non-assessable.
Anti-Takeover
Provisions
Certain provisions in our certificate of incorporation and
by-laws, as well as certain provisions of New Jersey law, may
make more difficult or discourage a takeover of our business.
Certain
Provisions of Our Certificate of Incorporation
We currently have the following provisions in our certificate of
incorporation which could be considered
anti-takeover provisions:
|
|
|
|
|
an article providing for a classified board of directors divided
into three classes, as nearly equal in number as possible, one
of which is elected at each annual meeting of stockholders. Such
article has been amended and the classification of our board of
directors will be phased out so that all directors will be
elected annually beginning with our 2011 annual shareholders
meeting;
|
|
|
|
an article requiring the affirmative vote of 80% of the
outstanding shares entitled to vote (voting together as a single
class) for certain merger and asset sale transactions with any
interested shareholder (generally, a 10% or greater
shareholder); and
|
8
|
|
|
|
|
an authorization for the issuance of blank check preferred
stock. As described above, our board of directors can set the
voting rights, redemption rights, conversion rights and other
rights relating to such preferred stock and could issue such
stock in either private or public transactions. In some
circumstances, the blank check preferred stock could be issued
and have the effect of preventing a merger, tender offer or
other takeover attempt that the board of directors opposes.
|
These provisions may have the effect of delaying, deferring or
preventing a change in control.
Anti-Takeover
Effects of the New Jersey Shareholders Protection
Act
We are subject to
Section 14A-10A
of the New Jersey Shareholders Protection Act, a type of
anti-takeover statute designed to protect stockholders against
coercive, unfair or inadequate tender offers and other abusive
tactics and to encourage any person contemplating a business
combination with us to negotiate with our board of directors for
the fair and equitable treatment of all stockholders. Subject to
certain qualifications and exceptions, the statute prohibits an
interested stockholder of a corporation from effecting a
business combination with the corporation for a period of five
years unless the corporations board of directors approved
the combination prior to the stockholder becoming an interested
stockholder. In addition, but not in limitation of the five-year
restriction, if applicable, corporations covered by the New
Jersey statute may not engage at any time in a business
combination with any interested stockholder of that corporation
unless the combination is approved by the board of directors
prior to the interested stockholders stock acquisition
date, the combination receives the approval of two-thirds of the
voting stock of the corporation not beneficially owned by the
interested stockholder or the combination meets minimum
financial terms specified by the statute.
An interested stockholder is defined to include any
beneficial owner of 10% or more of the voting power of the
outstanding voting stock of the corporation and any affiliate or
associate of the corporation who within the prior five year
period has at any time owned 10% or more of the voting power of
the then outstanding stock of the corporation.
The term business combination is defined broadly to
include, among other things:
|
|
|
|
|
the merger or consolidation of the corporation with the
interested stockholder or any corporation that is or after the
merger or consolidation would be an affiliate or associate of
the interested stockholder,
|
|
|
|
the sale, lease, exchange, mortgage, pledge, transfer or other
disposition to an interested stockholder or any affiliate or
associate of the interested stockholder of 10% or more of the
corporations assets, or
|
|
|
|
the issuance or transfer to an interested stockholder or any
affiliate or associate of the interested stockholder of 5% or
more of the aggregate market value of the stock of the
corporation.
|
The effect of the statute is to protect non-tendering,
post-acquisition minority stockholders from mergers in which
they will be squeezed out after the merger, by
prohibiting transactions in which an acquirer could favor itself
at the expense of minority stockholders. The statute generally
applies to corporations that are organized under New Jersey law,
have either, as of the date that the interested stockholder
first becomes an interested stockholder of the corporation,
their principal executive offices or significant business
operations located in New Jersey, and have a class of stock
registered or traded on a national securities exchange or
registered with the Securities and Exchange Commission pursuant
to Section 12(g) of the Securities Exchange Act of 1934.
Transfer
Agent and Registrar
The transfer agent and registrar for our common stock is
Computershare Trust Company, N.A.
DESCRIPTION
OF DEBT SECURITIES
The following description sets forth general terms and
provisions of the debt securities we may offer. The prospectus
supplement will describe the particular terms of the debt
securities being offered and the extent to which these general
provisions may apply to those debt securities.
9
The debt securities will be issued under the indenture, dated
March 1, 1997, between us and The Bank of New York
Mellon Trust Company N. A., as trustee. A copy of the indenture
is filed with the SEC as an exhibit to the registration
statement relating to this prospectus and you should refer to
the indenture for provisions that may be important to you.
General
The debt securities covered by this prospectus will be our
unsecured and unsubordinated obligations. The indenture does not
limit the aggregate principal amount of debt securities we can
issue. The indenture provides that debt securities may be issued
thereunder from time to time in one or more series.
The prospectus relating to any series of debt securities being
offered will include specific terms relating to the offering.
These terms will include some or all of the following:
|
|
|
|
|
the designation of the debt securities of the series;
|
|
|
|
any limit upon the aggregate principal amount of the debt
securities of the series and any limitation on our ability to
increase the aggregate principal amount of debt securities of
that series after initial issuance;
|
|
|
|
any date on which the principal of the debt securities of the
series is payable (which date may be fixed or extendible);
|
|
|
|
the interest rate or rates and the method for calculating the
interest rate;
|
|
|
|
if other than as provided in the indenture, any place where
principal of and interest on debt securities of the series will
be payable, where debt securities of the series may be
surrendered for exchange, where notices or demands may be served
and where notice to holders may be published and any time of
payment at any place of payment;
|
|
|
|
whether we have a right to redeem debt securities of the series
and any terms thereof;
|
|
|
|
whether you have a right to require us to redeem, repurchase or
repay debt securities of the series and any terms thereof;
|
|
|
|
if other than denominations of $1,000 and any integral multiple,
the denominations in which debt securities of the series shall
be issuable;
|
|
|
|
if other than the principal amount, the portion of the principal
amount of debt securities of the series which will be payable
upon declaration of acceleration of the maturity;
|
|
|
|
if other than U.S. dollars, the currency or currencies in
which payment of the principal of and interest on the debt
securities of the series will be payable;
|
|
|
|
whether the principal and any premium or interest is payable in
a currency other than the currency in which the debt securities
are denominated;
|
|
|
|
whether we have an obligation to pay additional amounts on the
debt securities of the series in respect of any tax, assessment
or governmental charge withheld or deducted and any right that
we may have to redeem those debt securities rather than pay the
additional amounts;
|
|
|
|
if other than the person acting as trustee, any agent acting
with respect to the debt securities of the series;
|
|
|
|
any provisions for the defeasance of any debt securities of the
series in addition to, in substitution for or in modification of
the provisions described in Defeasance and
Covenant Defeasance;
|
|
|
|
the identity of any depositary for registered global securities
of the series other than The Depository Trust Company and
any circumstances other than those described in
Global Securities in which any person
may have the right to obtain debt securities in definitive form
in exchange;
|
|
|
|
any events of default applicable to any debt securities of the
series in addition to, in substitution for or in modification of
those described in Events of Default;
|
10
|
|
|
|
|
any covenants applicable to any debt securities of the series in
addition to, in substitution for or in modification of those
described in Covenants; and
|
|
|
|
any other terms of the debt securities of the series.
|
The debt securities will be issued in registered form without
coupons unless otherwise provided in a supplemental indenture or
board resolution. Unless otherwise provided in a prospectus
supplement, principal (unless the context otherwise requires,
principal includes premium, if any) of and any
interest on the debt securities will be payable, and the debt
securities will be exchangeable and transfers thereof will be
registrable, at an office or agency designated for the debt
securities, provided that, at our option, payment of interest
may be made by check to the address of the person entitled
thereto as it appears in the security register. Subject to the
limitations provided in the indenture, such services will be
provided without charge, other than any tax or other
governmental charge payable in connection therewith.
Debt securities may be issued under the indenture as original
issue discount securities to be offered and sold at a
substantial discount from the principal amount. If any debt
securities are original issue discount securities, special
federal income tax, accounting and other considerations may
apply and will be described in the prospectus supplement
relating to the debt securities. Original Issue Discount
Security means any security which provides for an amount
less than the principal amount to be due and payable upon
acceleration of the maturity due to the occurrence and
continuation of an event of default.
Consolidation,
Merger and Sale of Assets
We have agreed not to consolidate or merge with any other
person, sell, transfer, lease or otherwise dispose of all or
substantially all of our properties and assets as an entirety
unless:
|
|
|
|
|
we are the surviving person; or
|
|
|
|
the surviving person is a corporation organized and validly
existing under the laws of the United States of America or any
U.S. State or the District of Columbia and expressly
assumes by a supplemental indenture all of our obligations under
the debt securities and under the indenture; and
|
|
|
|
immediately before and after the transaction or each series of
transactions, no default or event of default shall have occurred
and be continuing; and
|
|
|
|
certain other conditions are met.
|
Upon any such consolidation, merger, sale, transfer, lease or
other disposition, the surviving corporation will succeed to,
and be substituted for, and may exercise every right and power
that we have under the indenture and under the debt securities.
Events of
Default
The following are events of default under the
indenture with respect to debt securities of any series:
|
|
|
|
|
default in the payment of interest on any debt security when
due, which continues for 30 days;
|
|
|
|
default in the payment of principal of any debt security when
due;
|
|
|
|
default in the deposit of any sinking fund payment when due;
|
|
|
|
default in the performance of any other obligation contained in
the indenture, which default continues for 60 days after we
receive written notice of it from the trustee or from the
holders of 25% in principal amount of the outstanding debt
securities of that series;
|
|
|
|
specified events of bankruptcy, insolvency or reorganization of
our company for the benefit of our creditors; or
|
|
|
|
any other event of default established for the debt securities
of that series.
|
11
If an event of default for any series of debt securities occurs
and is continuing, the trustee or the holders of at least 25% in
aggregate principal amount of the debt securities of the series
may require us to repay immediately:
|
|
|
|
|
the entire principal of the debt securities of that
series; or
|
|
|
|
if the debt securities are original issue discount securities,
that portion of the principal as may be described in the
applicable prospectus supplement.
|
At any time after a declaration of acceleration with respect to
debt securities of any series has been made, but before a
judgment or decree based on that acceleration has been obtained,
the holders of a majority in principal amount of the debt
securities of that series may, under certain circumstances,
waive all defaults with respect to that series and rescind and
annul the acceleration.
We are required to furnish to the trustee annually an
Officers Certificate as to our compliance with all
conditions and covenants under the indenture. We must notify the
trustee within five days of any default or event of default.
The indenture provides that the trustee will, within
60 days after the occurrence of a default with respect to
the debt securities of any series, give to the holders of the
debt securities notice of all defaults. In certain instances,
the trustee may withhold that notice if and so long as a
responsible officer in good faith determines that withholding
the notice is in the interest of the holders of the debt
securities. By default we mean any event which is,
or after notice or passage of time would be, an event of default.
The indenture provides that the holders of a majority in
aggregate principal amount of the then outstanding debt
securities, by notice to the trustee, may direct the time,
method and place of conducting any proceeding for any remedy
available to the trustee, or exercising any trust or power
conferred on the trustee.
Subject to the further conditions contained in the indenture,
the holders of a majority in aggregate principal amount
outstanding of the debt securities of any series may waive, on
behalf of the holders of all debt securities of that series, any
past default or event of default and its consequences except a
default or event of default:
|
|
|
|
|
in the payment of the principal of, or interest on, any debt
security of that series; or
|
|
|
|
in respect of a covenant or provision of such indenture which
cannot under the terms of the indenture be amended or modified
without the consent of the holder of each outstanding debt
security that is adversely affected thereby.
|
The applicable prospectus supplement will describe any
provisions for events of default applicable to the debt
securities of any series in addition to, in substitution for, or
in modification of, the provisions described above.
Covenants
We have agreed to some restrictions on our activities for the
benefit of holders of the debt securities. Unless we state
otherwise in a prospectus supplement, the restrictive covenants
summarized below will apply so long as any of the debt
securities are outstanding, unless the covenants are waived or
amended. The prospectus supplement may contain different
covenants. We have provided the definitions to define the
capitalized words used in describing the covenants.
Definitions
Attributable Debt means, with respect to a
lease, the total net amount of rent (discounted at a rate per
annum equivalent to the interest rate inherent in such lease, as
we determine in good faith, compounded semiannually) required to
be paid during the remaining term of such lease, including any
period for which such lease has been extended or may, at the
option of the lessor, be extended.
Consolidated Net Tangible Assets means the
total amount of our and our Restricted Subsidiaries assets
(less applicable reserves and other properly deductible items)
after deducting (i) all current liabilities (excluding any
liabilities constituting funded debt by reason of being
renewable or extendible), (ii) all goodwill, trade names,
trademarks, patents, unamortized debt discount and expense and
other like intangibles, (iii) investments in and
12
advances to subsidiaries which are not Restricted Subsidiaries,
and (iv) minority interests in the equity of Restricted
Subsidiaries.
Funded Debt means all indebtedness for
borrowed money maturing more than 12 months after the time
of computation thereof, guarantees of such indebtedness of
others (except guarantees of collection arising in the ordinary
course of business), and all obligations in respect of lease
rentals which, under generally accepted accounting principles,
are shown on a balance sheet as a non-current liability.
Principal Property means any building,
structure or other facility (together with the land on which it
is erected and fixtures comprising a part thereof) now owned or
hereafter acquired by us or any Restricted Subsidiary and used
primarily for manufacturing, processing or warehousing and
located in the United States (excluding its territories and
possessions, but including Puerto Rico), the gross book value
(without deduction of any depreciation reserves) of which is in
excess of 2.0% of Consolidated Net Tangible Assets, other than
any such building, structure or other facility or portion which,
in the opinion of our board of directors, is not of material
importance to the total business conducted by us and our
Restricted Subsidiaries as an entirety.
Restricted Subsidiary means any subsidiary
that substantially all of the property and operations of which
are located in the United States (excluding its territories and
possessions, but including Puerto Rico), and which owns or
leases a Principal Property, except a subsidiary which is
primarily engaged in the business of a finance company.
Subsidiary means a corporation more than 50%
of the outstanding voting stock of which is owned, directly or
indirectly, by us or by one or more other subsidiaries, or by us
and by one or more other subsidiaries.
Restrictions
on Secured Debt
If we or any Restricted Subsidiary incurs, issues, assumes or
guarantees any debt secured by a mortgage on any Principal
Property or on any shares of stock or debt of any Restricted
Subsidiary, we will secure, or cause such Restricted Subsidiary
to secure, the debt securities (and, if we choose, any other
debt of ours or that Restricted Subsidiary which is not
subordinate to the debt securities) equally and ratably with (or
prior to) such secured debt. However, we may incur secured debt
without securing this debt, if the aggregate amount of all such
debt so secured, together with all our and our Restricted
Subsidiaries Attributable Debt in respect of certain sale
and leaseback transactions involving Principal Properties, would
not exceed 10% of Consolidated Net Tangible Assets. This
restriction will not apply to, and we will exclude from our
calculation of secured debt for the purposes of this
restriction, debt secured by:
|
|
|
|
|
mortgages existing on properties on the date of the indenture,
|
|
|
|
mortgages on properties, shares of stock or debt existing at the
time of acquisition (including acquisition through merger or
consolidation), purchase money mortgages and construction
mortgages,
|
|
|
|
mortgages on property of, or on any shares of stock or debt of,
any corporation existing at the time that corporation becomes a
Restricted Subsidiary,
|
|
|
|
mortgages in favor of Federal and State governmental bodies to
secure progress, advance or other payments pursuant to any
contract or provision of any statute,
|
|
|
|
mortgages in favor of us or a Restricted Subsidiary,
|
|
|
|
mortgages in connection with the issuance of tax-exempt
industrial development bonds,
|
|
|
|
mortgages under workers compensation laws, unemployment
insurance laws or similar legislation, or deposit bonds to
secure statutory obligations (or pledges or deposits for similar
purposes in the ordinary course of business), or liens imposed
by law and certain other liens or other encumbrances, and
|
|
|
|
subject to certain limitations, any extension, renewal or
replacement of any mortgage referred to in the foregoing clauses.
|
13
Restrictions
on Sale and Leasebacks
We have agreed that we will not, and we will not permit any of
our Restricted Subsidiaries to, enter into any sale and
leaseback transaction involving the taking back of a lease, for
a period of three or more years, of any Principal Property, the
acquisition, completion of construction or commencement of full
operation of which has occurred more than 120 days prior
thereto, unless:
|
|
|
|
|
the commitment to enter into the sale and leaseback transaction
was obtained during that
120-day
period;
|
|
|
|
we or our Restricted Subsidiaries could create debt secured by a
mortgage on the Principal Property as described under
Restrictions on Secured Debt above in an
amount equal to the Attributable Debt with respect to the sale
and leaseback transaction without equally and ratably securing
the debt securities;
|
|
|
|
within 120 days after the sale or transfer, we designate an
amount to the retirement of Funded Debt, subject to credits for
voluntary retirements of Funded Debt, equal to the greater of
|
(i) the net proceeds of the sale of the Principal
Property and
(ii) the fair market value of the Principal
Property, or
|
|
|
|
|
we or any Restricted Subsidiary, within a period commencing
180 days prior to and ending 180 days after the sale
or transfer, have expended or reasonably expect to expend within
such period any monies to acquire or construct any Principal
Property or properties in which event we or that Restricted
Subsidiary enter into the sale and leaseback transaction, but
(unless certain other conditions are met) only to the extent
that the Attributable Debt with respect to the sale and
leaseback transaction is less than the monies expended or to be
expended.
|
These restrictions will not apply to any sale and leaseback
transactions between us and a Restricted Subsidiary or between a
Restricted Subsidiary and another Restricted Subsidiary.
Modification
and Waiver
Under the indenture we and the trustee may enter into one or
more supplemental indentures without the consent of the holders
of debt securities in order to:
|
|
|
|
|
evidence the succession of another corporation to our company
and the assumption of our covenants by that successor,
|
|
|
|
provide for a successor trustee with respect to the debt
securities of all or any series,
|
|
|
|
establish the forms and terms of the debt securities of any
series,
|
|
|
|
provide for uncertificated or unregistered debt
securities, or
|
|
|
|
cure any ambiguity or correct any mistake or to make any change
that does not materially adversely affect the legal rights of
any holder of the debt securities under the indenture.
|
We and the trustee may, with the consent of the holders of a
majority in principal amount of the outstanding debt securities
of each affected series, amend the indenture and the debt
securities of any series for the purpose of adding any
provisions to or changing or eliminating any provisions of the
indenture or modifying the rights of holders of debt securities
under the indenture. However, without the consent of each holder
of any debt security affected, we may not amend or modify the
indenture to:
|
|
|
|
|
change the stated maturity date of any installment of principal
of, or interest on, any debt security,
|
|
|
|
reduce the principal amount of, or the rate of interest on, any
debt security,
|
|
|
|
adversely affect the rights of any debt security holder under
any mandatory redemption or repurchase provision,
|
|
|
|
reduce the amount of principal of an original issue discount
security payable upon acceleration of its maturity,
|
14
|
|
|
|
|
change the place or currency of payment of principal of, or any
premium or interest on, any debt security,
|
|
|
|
impair the right to institute suit for the enforcement of any
payment or delivery on or with respect to any debt security,
|
|
|
|
reduce the percentage in principal amount of debt securities of
any series, the consent of whose holders is required to modify
or amend the indenture or to waive compliance with certain
provisions of the indenture,
|
|
|
|
reduce the percentage in principal amount of debt securities of
any series, the consent of whose holders is required to waive
any past default,
|
|
|
|
waive a default in the payment of principal of, or interest on,
any debt security, or
|
|
|
|
change any of our obligations to maintain offices or agencies
where the debt securities may be surrendered for payment,
registration or transfer and where notices and demands may be
served upon us.
|
Defeasance
and Covenant Defeasance
When we use the term defeasance, we mean discharge
from some or all of our obligations under the indenture. Unless
the terms of the debt securities of any series provide
otherwise, we may elect either:
|
|
|
|
|
to defease and be discharged from any and all obligations with
respect to
|
|
|
|
|
|
debt securities of any series payable within one year, or
|
|
|
|
other debt securities of any series upon the conditions
described below; or
|
|
|
|
|
|
to be released from our obligations with respect to covenants
described under Covenants above and, if
specified in the prospectus supplement, other covenants
applicable to the debt securities of any series (covenant
defeasance),
|
upon (or, with respect to defeasance of debt securities payable
later than one year from the date of defeasance, on the
91st day after) the deposit with the trustee, in trust for
that purpose, of money
and/or
U.S. Government obligations which through the payment of
principal and interest in accordance with their terms will
provide money in an amount sufficient without reinvestment to
pay the principal of and interest on the debt securities.
As a condition to defeasance of any debt securities of any
series payable later than one year from the time of defeasance,
we must deliver to the trustee an opinion of counsel
and/or a
ruling of the Internal Revenue Service to the effect that
holders of the debt securities will not recognize income, gain
or loss for Federal income tax purposes as a result of that
defeasance and will be subject to Federal income tax on the same
amount and in the same manner and at the same times as would
have been the case if the defeasance or covenant defeasance had
not occurred.
We may exercise either defeasance option with respect to the
debt securities of any series notwithstanding our prior exercise
of our covenant defeasance option. If we exercise our defeasance
option, payment of the debt securities of any series may not be
accelerated because of a default or an event of default. If we
exercise our covenant defeasance option, payment of the debt
securities of any series may not be accelerated by reason of an
event of default with respect to the covenants to which the
covenant defeasance applies. If acceleration were to occur by
reason of another event of default, the realizable value at the
acceleration date of the money and U.S. Government
obligations in the defeasance trust could be less than the
principal and interest then due on the debt securities. In other
words, the required deposit in the defeasance trust is based
upon scheduled cash flow rather than market value, which will
vary depending upon interest rates and other factors. We will,
however, remain liable for such payments at the time of the
acceleration.
Governing
Law
The indenture and the debt securities are governed by and
construed in accordance with the laws of the State of New York.
15
The
Trustee
We maintain a banking relationship with the trustee. An
affiliate of the trustee is also one of the broker-dealers we
use in connection with our share repurchase program.
DESCRIPTION
OF WARRANTS
We may issue warrants to purchase debt securities or common
stock. We may offer warrants separately or together with one or
more additional warrants, debt securities or common stock, or
any combination of those securities in the form of units, as
described in the applicable prospectus supplement. If we issue
warrants as part of a unit, the prospectus supplement will
specify whether those warrants may be separated from the other
securities in the unit prior to the warrants expiration
date. Below is a description of the general terms and provisions
of the warrants that we may offer. Further terms of the warrants
will be described in the prospectus supplement.
The prospectus supplement will contain, where applicable, the
following terms of and other information relating to the
warrants:
|
|
|
|
|
the specific designation and aggregate number of, and the price
at which we will issue, the warrants;
|
|
|
|
the currency or currency units in which the offering price, if
any, and the exercise price are payable;
|
|
|
|
the date on which the right to exercise the warrants will begin
and the date on which that right will expire or, if you may not
continuously exercise the warrants throughout that period, the
specific date or dates on which you may exercise the warrants;
|
|
|
|
whether the warrants will be issued in fully registered form or
bearer form, in definitive or global form or in any combination
of these forms, although, in any case, the form of a warrant
included in a unit will correspond to the form of the unit and
of any security included in that unit;
|
|
|
|
any applicable material U.S. federal income tax
consequences;
|
|
|
|
the identity of the warrant agent for the warrants and of any
other depositories, execution or paying agents, transfer agents,
registrars or other agents;
|
|
|
|
the proposed listing, if any, of the warrants or any securities
purchasable upon exercise of the warrants on any securities
exchange;
|
|
|
|
whether the warrants are to be sold separately or with other
securities as parts of units;
|
|
|
|
if applicable, the designation and terms of the debt securities
or common stock with which the warrants are issued and the
number of warrants issued with each security;
|
|
|
|
if applicable, the date from and after which the warrants and
the related debt securities or common stock will be separately
transferable;
|
|
|
|
the designation, aggregate principal amount, currency and terms
of the debt securities that may be purchased upon exercise of
the warrants;
|
|
|
|
the number of shares of common stock purchasable upon exercise
of a warrant and the price at which those shares may be
purchased;
|
|
|
|
if applicable, the minimum or maximum amount of the warrants
that may be exercised at any one time;
|
|
|
|
information with respect to book-entry procedures, if any;
|
|
|
|
any antidilution provisions of the warrants;
|
|
|
|
any redemption or call provisions; and
|
|
|
|
any additional terms of the warrants, including terms,
procedures and limitations relating to the exchange and exercise
of the warrants.
|
16
DESCRIPTION
OF PURCHASE CONTRACTS
We may issue purchase contracts for the purchase or sale of:
|
|
|
|
|
debt securities or equity securities issued by us or securities
of third parties, a basket of such securities, an index or
indices of such securities or any combination as specified in
the applicable prospectus supplement;
|
|
|
|
currencies; or
|
|
|
|
commodities.
|
We may issue purchase contracts obligating holders to purchase
from us, and obligating us to sell to holders, a specified or
varying number of securities, currencies or commodities at a
purchase price, which may be based on a formula, at a future
date. Alternatively, we may issue purchase contracts obligating
us to purchase from holders, and obligating holders to sell to
us, a specified or varying number of securities, currencies or
commodities at a purchase price, which may be based on a
formula, at a future date. We may be entitled to satisfy our
obligations, if any, with respect to any purchase contract by
delivering the cash value of that purchase contract or the cash
value of the property otherwise deliverable or, in the case of
purchase contracts on underlying currencies, by delivering the
underlying currencies, as set forth in the prospectus
supplement. The prospectus supplement will specify the methods
by which the holders may purchase or sell those securities,
currencies or commodities and any acceleration, cancellation or
termination provisions or other provisions relating to the
settlement of a purchase contract. The purchase contracts may be
entered into separately or as a part of units.
The purchase contracts may require us to make periodic payments
to the holders thereof or vice versa, and these payments may be
unsecured or prefunded and may be paid on a current or deferred
basis. The purchase contracts may require holders to secure
their obligations under the contracts in a specified manner to
be described in the prospectus supplement. Alternatively,
purchase contracts may require holders to satisfy their
obligations thereunder when the purchase contracts are issued.
DESCRIPTION
OF UNITS
As specified in the applicable prospectus supplement, we may
issue units consisting of one or more purchase contracts,
warrants, debt securities, shares of common stock or any
combination of these securities, or securities of other
entities. The prospectus supplement will describe:
|
|
|
|
|
the terms of the units and of the purchase contracts, warrants,
debt securities and common stock comprising the units, including
whether and under what circumstances the securities comprising
the units may be traded separately;
|
|
|
|
a description of the terms of any unit agreement governing the
units; and
|
|
|
|
a description of the provisions for the payment, settlement,
transfer or exchange of the units.
|
FORMS OF
SECURITIES
Each debt security, warrant and unit will be represented either
by a certificate issued in definitive form to a particular
investor or by one or more global securities representing the
entire issuance of securities. Certificated securities in
definitive form and global securities will be issued in
registered form. Definitive securities name you or your nominee
as the owner of the security, and in order to transfer or
exchange these securities or to receive payments other than
interest or other interim payments, you or your nominee must
physically deliver the securities to the trustee, registrar,
paying agent or other agent, as applicable. Global securities
name a depositary or its nominee as the owner of the debt
securities, warrants or units represented by these global
securities. The depositary maintains a computerized system that
will reflect each investors beneficial ownership of the
securities through an account maintained by the investor with
its broker/dealer, bank, trust company or other representative,
as we explain more fully below.
17
Registered
global securities
The debt securities of each series will be issued in the form of
one or more fully registered global debt securities that are
registered in the name of The Depository Trust Company, or
its nominee, as depositary, unless another depositary is
designated for the debt securities of that series. Unless we
state otherwise in a prospectus supplement, debt securities in
definitive form will not be issued. Unless and until a global
security is exchanged in whole or in part for debt securities in
definitive form, it may not be registered for transfer or
exchange except as a whole by the depositary for that global
security to a nominee of the depositary.
Upon the issuance of any global security, and its deposit with
or on behalf of the depositary, the depositary will credit, on
its book-entry registration and transfer system, the respective
principal amounts of the debt securities represented by that
global security to the accounts of institutions, the
participants that are entitled to the registered global security
that have accounts with the depositary designated by the
underwriters or their agents engaging in any distribution of the
debt securities. The depositary advises that pursuant to
procedures established by it:
|
|
|
|
|
Ownership of beneficial interests in a global security will be
limited to participants or persons that may hold interests
through participants.
|
|
|
|
Ownership of beneficial interests by participants in a global
security will be shown on, and the transfer of the beneficial
interests will be effected only through, records maintained by
the depositary or by its nominee.
|
|
|
|
Ownership of beneficial interests in a global security by
persons that hold through participants will be shown on, and the
transfer of those beneficial interests will be effected only
through, records maintained by the participants.
|
The laws of some jurisdictions require that certain purchasers
of securities take physical delivery of the securities in
certificated form. The foregoing limitations and these laws may
impair your ability to own, transfer or pledge beneficial
interests in global securities.
As long as the depositary, or its nominee, is the registered
owner of a global security, the depositary or its nominee, will
be considered the sole owner or holder of the debt securities
represented by the global security for all purposes under the
indenture. Except as specified below, owners of beneficial
interests in a global security will not:
|
|
|
|
|
be entitled to have their debt securities represented by the
global security registered in their names;
|
|
|
|
receive or be entitled to receive physical delivery of debt
securities in certificated form; or
|
|
|
|
be considered the holders for any purposes under the indenture.
|
Accordingly, each person owning a beneficial interest in a
global security must rely on the procedures of the depositary
and, if the person is not a participant, on the procedures of
the participant through which that person holds its interest, in
order to exercise any rights of a holder of debt securities
under the indenture. The depositary may grant proxies and
otherwise authorize participants to give or take any request,
demand, authorization, direction, notice, consent, waiver or
other action which a holder of debt securities is entitled to
give or take under the indenture.
We understand that, under existing industry practices, if we
request any action of holders of debt securities or any owner of
a beneficial interest in a global security desires to give any
notice or take any action a holder of debt securities is
entitled to give or take under the indenture, the depositary
would authorize the participants holding the relevant beneficial
interests to give that notice or take that action, and the
participants would authorize the beneficial owners owning
through them to give the notice or take the action or would
otherwise act upon the instructions of the beneficial owners
owning through them.
The depositary or a nominee thereof, as holder of record of a
global security, will be entitled to receive payments of
principal and interest for payment to beneficial owners in
accordance with customary procedures established from time to
time by the depositary. The agent for the payment, transfer and
exchange of the securities is the trustee, acting through its
corporate trust office located in the Borough of Manhattan, The
City of New York.
We expect that the depositary, upon receipt of any payment of
principal or interest in respect of a global security, will
immediately credit participants accounts with payments in
amounts proportionate to their respective
18
beneficial interests in the principal amount of the global
security as shown on the records of the depositary. We also
expect that payments by participants to owners of beneficial
interests in a global security held through the participants
will be governed by standing instructions and customary
practices, and will be the responsibility of the participants.
We, the trustee, our agents and the trustees agents shall
not have any responsibility or liability for any aspect of the
records relating to or payments made on account of beneficial
ownership interests in a global security, or for maintaining,
supervising or reviewing any records relating to those
beneficial ownership interests.
If we determine that debt securities will no longer be
maintained as global securities, or, if at any time an event of
default has occurred and is continuing under the indenture, or
if the depositary is at any time unwilling or unable to continue
as depositary or ceases to be a clearing agency registered or in
good standing under the Exchange Act, and a successor depositary
registered as a clearing agency under the Exchange Act is not
appointed by us within 90 days, we will issue debt
securities in definitive certificated form in exchange for the
registered global securities.
In the event that the book-entry system is discontinued, the
following provisions shall apply. The trustee or any successor
registrar under the indenture shall keep a register for the debt
securities in definitive certificated form at its corporate
trust office. Subject to the further conditions contained in the
indenture, debt securities in definitive certificated form may
be transferred or exchanged for one or more debt securities in
different authorized denominations upon surrender of the debt
securities at the corporate trust office of the trustee or any
successor registrar under the indenture by the registered
holders or their duly authorized attorneys. Upon surrender of
any debt security to be transferred or exchanged, the trustee or
any successor registrar under the indenture shall record the
transfer or exchange in the security register and we will issue,
and the trustee shall authenticate and deliver, new debt
securities in definitive certificated form appropriately
registered and in appropriate authorized denominations. The
trustee shall be entitled to treat the registered holders of the
debt securities in definitive certificated form, as their names
appear in the security register as of the appropriate date, as
the owners of the debt securities for all purposes under the
indenture.
PLAN OF
DISTRIBUTION
BD may sell the securities in one or more of the following ways
(or in any combination) from time to time:
|
|
|
|
|
through underwriters or dealers;
|
|
|
|
directly to a limited number of purchasers or to a single
purchaser; or
|
|
|
|
through agents.
|
The prospectus supplement will state the terms of the offering
of the securities, including:
|
|
|
|
|
the name or names of any underwriters, dealers or agents;
|
|
|
|
the purchase price of such securities and the proceeds to be
received by BD;
|
|
|
|
any underwriting discounts or agency fees and other items
constituting underwriters or agents compensation;
|
|
|
|
any initial public offering price;
|
|
|
|
any discounts or concessions allowed or reallowed or paid to
dealers; and
|
|
|
|
any securities exchanges on which the securities may be listed.
|
Any initial public offering price and any discounts or
concessions allowed or reallowed or paid to dealers may be
changed from time to time.
If we use underwriters in the sale, the securities will be
acquired by the underwriters for their own account and may be
resold from time to time in one or more transactions, including:
|
|
|
|
|
negotiated transactions;
|
|
|
|
at a fixed public offering price or prices, which may be changed;
|
19
|
|
|
|
|
at market prices prevailing at the time of sale;
|
|
|
|
at prices related to prevailing market prices; or
|
|
|
|
at negotiated prices.
|
Unless otherwise stated in a prospectus supplement, the
obligations of the underwriters to purchase any securities will
be conditioned on customary closing conditions and the
underwriters will be obligated to purchase all of such series of
securities, if any are purchased.
We may sell the securities through agents from time to time. The
prospectus supplement will name any agent involved in the offer
or sale of the securities and any commissions we pay to them.
Generally, any agent will be acting on a best efforts basis for
the period of its appointment.
We may authorize underwriters, dealers or agents to solicit
offers by certain purchasers to purchase the securities from BD
at the public offering price set forth in the prospectus
supplement pursuant to delayed delivery contracts providing for
payment and delivery on a specified date in the future. The
contracts will be subject only to those conditions set forth in
the prospectus supplement, and the prospectus supplement will
set forth any commissions we pay for solicitation of these
contracts.
Underwriters and agents may be entitled under agreements entered
into with BD to indemnification by BD against certain civil
liabilities, including liabilities under the Securities Act, or
to contribution with respect to payments that the underwriters
or agents may be required to make. Underwriters and agents may
be customers of, engage in transactions with, or perform
services for BD and its affiliates in the ordinary course of
business.
Each series of securities other than the common stock, which is
listed on the NYSE, will be a new issue of securities and will
have no established trading market. Any underwriters to whom
securities are sold for public offering and sale may make a
market in the securities, but such underwriters will not be
obligated to do so and may discontinue any market making at any
time without notice. The securities, other than the common
stock, may or may not be listed on a national securities
exchange.
VALIDITY
OF SECURITIES
Unless otherwise indicated in the prospectus supplement with
respect to any securities, the validity of the securities will
be passed upon for us by Jeffrey S. Sherman, our Senior Vice
President and General Counsel.
EXPERTS
The consolidated financial statements of Becton, Dickinson and
Company incorporated by reference in Becton, Dickinson and
Companys Annual Report
(Form 10-K)
for the year ended September 30, 2008 (including the
schedule appearing therein) have been audited by
Ernst & Young LLP, independent registered public
accounting firm, as set forth in their report thereon,
incorporated by reference therein, and incorporated herein by
reference. Such consolidated financial statements are
incorporated herein by reference in reliance upon such report
given on the authority of such firm as experts in accounting and
auditing.
20
$1,000,000,000
Becton, Dickinson and
Company
$700,000,000 3.25% Notes
due November 12, 2020
$300,000,000 5.00% Notes
due November 12, 2040
PROSPECTUS SUPPLEMENT
Joint
Book-Running Managers
|
|
|
Goldman, Sachs &
Co.
|
|
Morgan Stanley
|
|
|
|
(2020 Notes)
|
|
(2040 Notes)
|
J.P. Morgan
|
|
Citi
|
Co-Managers
Mitsubishi UFJ Securities
|
|
|
|
|
BofA
Merrill Lynch |
BBVA
Securities |
BNP
PARIBAS |
Mizuho
Securities USA Inc. |
|
|
|
|
|
Banca
IMI |
Standard
Chartered Bank |
Wells
Fargo Securities |
|
|
|
|
BNY
Mellon Capital Markets, LLC |
Credit
Agricole CIB |
|